金原一郎記念医学医療振興財団　第13回研究交流助成金

1999.1   金原一郎記念医学医療振興財団  

RMBC (Respiratory Molecular Cell Biology) 研究会助成金受賞

1998.6  

AACR-ITOEN, Young Investigation Award For Promising Cancer Research

1998.1   AACR-ITOEN(American Association for Cancer Research)-ITOEN  

MicroRNA-326 negatively regulates CD155 expression in lung adenocarcinoma Invited Reviewed International journal

Nakanishi T., Yoneshima Y., Okamura K., Yanagihara T., Hashisako M., Iwasaki T., Haratake N., Mizusaki S., Ota K., Iwama E., Takenaka T., Tanaka K., Yoshizumi T., Oda Y. & Okamoto I.

Cancer Science   114 ( 10 )   4101 - 4113   2023.10

Regulation of PD-L1 expression in non–small cell lung cancer by interleukin-1β Invited Reviewed International journal

14   2023.8

Evaluation of appropriate conditions for Oncomine DxTT testing of FFPE specimens for driver gene alterations in non-small cell lung cancer Invited Reviewed International journal

Iwama E., Yamamoto H., Okubo F., Ijichi K., Ibusuki R., Shiaraishi Y., Yoneshima Y., Tanaka K., Oda Y. & Okamoto I.

Thoracic Cancer   14 ( 23 )   2288 - 2296   2023.8

Impact of increased plasma levels of calreticulin on prognosis of patients with advanced lung cancer undergoing combination treatment of chemotherapy and immune checkpoint inhibitors Invited Reviewed International journal

Tsutsumi H.,Inoue H., Shiraishi Y., Hirayama A., Nakanishi T., Ando H., Nakajima M., Shinozaki S.,Ogata H., Okamura K., Kimura S., Ogawa T., Ota K., Yoneshima Y., Tanaka K., Hamada N., Okamoto I. & Iwama E.

Lung Cancer   181   2023.7

Mutant forms of EGFR promote HER2 trafficking through efficient formation of HER2-EGFR heterodimers Reviewed International journal

Tsutsumi H., Iwama E., Ibusuki R., Shimauchi A., Ota K., Yoneshima Y., Inoue H., Tanaka K., Nakanishi Y. & Okamoto I.

Lung Cancer   2023.1

Nintedanib plus chemotherapy for non–small cell lung cancer with IPF: a randomized phase 3 trial Reviewed International journal

2022.12

Phase II study of carboplatin/nab-paclitaxel/atezolizumab combination therapy for advanced nonsquamous non-small cell lung cancer patients with impaired renal function: RESTART trial Reviewed International journal

Shiraishi Y., Kishimoto J., Shimose T., Toi Y., Sugawara S. & Okamoto I.

BMC Cancer   2022.12

Association of thyroid transcription factor-1 (TTF-1) expression with efficacy of PD-1/PD-L1 inhibitors plus pemetrexed and platinum chemotherapy in advanced non-squamous non-small cell lung cancer Reviewed International journal

Ibusuki R., Yoneshima Y., Hashisako M., Matsuo N., Harada T., Tsuchiya-Kawano Y., Kishimoto J., Ota K., Shiraishi Y., Iwama E., Tanaka K., Oda Y. & Okamoto I.

Translational Lung Cancer Research   2022.12

Forthcoming Phase II Study of Durvalumab (MEDI4736) Plus Chemotherapy for Small Cell Lung Cancer with Brain Metastases Reviewed International journal

Shiraishi Y., Shimose T., Tsuchiya-Kawano Y., Ishii H., Daga H., Ito K., Saruwatari K. & Okamoto I.

Cancer Management and Research   2022.12

Combination bezafibrate and nivolumab treatment of patients with advanced non-small cell lung cancer Invited Reviewed International journal

Tanaka K., Chamoto K., Saeki S., Hatae R., Ikematsu Y., Sakai K., Ando N., Sonomura K., Kojima S., Taketsuna M., Hak Kim Y., Yoshida H., Ozasa H., Sakamori Y., Hirano T., Matsuda F., HiraiT., Nishio K., Sakagami T., Fukushima M., Nakanishi Y., HonjoT. & Okamoto I.

Science Translational Medicine   2022.12

Immunostimulatory oncolytic activity of coxsackievirus A11 in human malignant pleural mesothelioma Reviewed International journal

Okamura K., Inoue H., Tanaka K., Ikematsu Y., Furukawa R., Ota K., Yoneshima Y., Iwama E. & Okamoto I.

Cancer Science   2022.11

Nab-Paclitaxel for Previously Treated Advanced Non–Small Cell Lung Cancer: Analysis of Safety and Efficacy for Patients With Renal Impairment Reviewed International journal

2022.11

Trastuzumab emtansine for patients with non–small cell lung cancer positive for human epidermal growth factor receptor 2 exon-20 insertion mutations Invited Reviewed International journal

2022.2

The CLIP1–LTK fusion is an oncogenic driver in non‐small‐cell lung cancer Invited Reviewed International journal

Izumi H., Matsumoto S., Liu J., Tanaka K. Mori S., Hayashi K., Kumagai S., Shibata Y., Hayashida T., Watanabe K., Fukuhara T., Ikeda T., Yoh K., Kato T., Nishino K., Nakamura A., Nakachi I., Kuyama S., Furuya N., Sakakibara – Konishi J., Okamoto I., Taima K., Ebi N., Daga H., Yamasaki A., Kodani M., Udagawa H., Kirita K., Zenke Y., Nosaki K., Sugiyama E., Sakai T., Nakai T., Ishii G., Niho S., Ohtsu A., Kobayashi S. & Goto K.

2021.12

Phase ii study of nivolumab plus ipilimumab with platinum-based chemotherapy for treatment-naïve advanced non-small cell lung cancer with untreated brain metastases: Nike trial (logik2004) Invited Reviewed International journal

2021.11

A Multicenter, Randomized Phase III Study Comparing Platinum Combination Chemotherapy Plus Pembrolizumab With Platinum Combination Chemotherapy Plus Nivolumab and Ipilimumab for Treatment-Naive Advanced Non–Small Cell Lung Cancer Without Driver Gene Alterations: JCOG2007 (NIPPON Study) Invited Reviewed International journal

2021.10

First-Line Pembrolizumab Versus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer: KEYNOTE-024 Japan Subset Invited Reviewed International journal

2021.9

Efficacy and Safety of Rovalpituzumab Tesirine as Second-Line Therapy in DLL3-High Small-Cell Lung Cancer: Results from the Phase 3 TAHOE Study Invited Reviewed International journal

Blackhall F., Jao K., Greillier L., Cho BC., Penkov K., Reguart N., Majem M., Nackaerts K., Syrigos K., Hansen K., Schuette W., Cetnar J., Cappuzzo F., Okamoto I., Erman M., Langer SW., Kato T., Groen H., Sun Z., Luo Y., Tanwani P., Caffrey L., Komarnitsky P. & Reinmuth N.

Journal of Thoracic Oncology   2021.9

Rovalpituzumab Tesirine as a Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Patients With Extensive-Stage Small Cell Lung Cancer: Results From the Phase 3 MERU Study Invited Reviewed International journal

Johnson ML., Zvirbule Z., Laktionov K., Helland A., Cho BC., Gutierrez V., Colinet B., Lena H., Wolf M., Gottfried M., Okamoto I., Leest C., Rich P., Hung JY., Appenzeller C., Zhaowen S., Maag D., Luo Y., Nickner C., Vajikova A., Komarnitsky P. & Bar J.

Journal of Thoracic Oncology   2021.9

Quantification of HER family dimers by proximity ligation assay and its clinical evaluation in non–small cell lung cancer patients treated with osimertinib Invited Reviewed International journal

2021.8

Paired analysis of tumor mutation burden for lung adenocarcinoma and associated idiopathic pulmonary fibrosis. Invited Reviewed International journal

Yoneshima Y, Iwama E, Matsumoto S, Matsubara T, Tagawa T, Ota K, Tanaka K, Takenoyama M, Okamoto T, Goto K, Mori M, Okamoto I.

Scientific Reports   2021.7

A Phase II Study of Osimertinib in EGFR¬-Mutated Non–Small Cell Lung Cancer Patients with Isolated Central Nervous System Progression (EGFR-T790M Negative or Unknown) after First- or Second-Generation Tyrosine Kinase Inhibitor Therapy or with Systemic Disease Progression (T790M Negative) after both such Treatment and Platinum-Based Chemotherapy (WJOG12819L) Invited Reviewed International journal

2021.7

Clinical impact of probiotics on the efficacy of anti-PD-1 monotherapy in patients with non-small cell lung cancer: A multicenter retrospective survival analysis study with inverse probability of treatment weighting Invited Reviewed International journal

Takada K., Shimokawa M., Takamori S., Shimamatsu S., Hirai F., Tagawa T., Okamoto T., Hamatake M., Tsuchiya Y., Otsubo K., Inoue K., Yoneshima Y., Tanaka K., Okamoto I., Nakanishi Y. & Mori M.

International Journal of Cancer   2021.7

Prognostic significance of pre-treatment ALBI grade in advanced non-small cell lung cancer receiving immune checkpoint therapy. Invited Reviewed International journal

Matsukane R., Watanabe H., Hata K., Suetsugu K., Tsuji T., Egashira N., Nakanishi Y., Okamoto I. & Ieiri I.

Scientific Reports   2021.7

Increased plasma levels of damage-associated molecular patterns during systemic anticancer therapy in patients with advanced lung cancer Invited Reviewed International journal

Inoue H., Tsutsumi H., Tanaka K., Iwama E, Shiraishi Y., Hirayama A., Nakanishi T., Ando H., Nakajima M., Shinozaki S., Ogata H., Uryu K., Okamura K., Kimura S., Ogawa T., Ota K., Yoneshima Y, Hamada N., Nakanishi Y. & Okamoto I.

Translational Lung Cancer Research   2021.6

Prognostic impact of primary cancer adjoining emphysematous bullae in non-small-cell lung cancer patients treated with immune checkpoint inhibitors. Invited Reviewed International journal

Takamori S., Takada K., Shimokawa M., Jinnouchi M., Matsubara T., Haratake N., Miura N., Toyozawa R., Yamaguchi M., Takenoyama M., Yoneshima Y., Tanaka K., Okamoto I., Tagawa T. & Mori M.

Cancer Immunology Immunotherapy   2021.6

First-line durvalumab plus platinum-etoposide in extensive-stage small-cell lung cancer: CASPIAN Japan subgroup analysis. Invited Reviewed International journal

Hotta K., Nishio M., Saito H., Okamoto I., Nakahara Y., Hayashi H., Hayama M., Laud P., Jiang H., Paz-Ares L. & Azuma K.

International Journal of Clinical Oncology   2021.6

Biomarker-Directed Phase II Platform Study in Patients With EGFR Sensitizing Mutation-Positive Advanced/Metastatic Non-Small Cell Lung Cancer Whose Disease Has Progressed on First-Line Osimertinib Therapy (ORCHARD). Invited Reviewed International journal

Yu HA., Goldberg SB., Le X., Piotrowska Z., Goldman JW., De Langen AJ., Okamoto I., Cho BC., Smith P., Mensi I., Ambrose H., Kraljevic S., Maidment J., Chmielecki J., Li-Sucholeiki X., Doughton G., Patel G., Jewsbury P., Szekeres P. & Riess JW.

Clinical Lung Cancer   2021.6

Cytotoxic chemotherapeutic agents and the EGFR-TKI osimertinib induce calreticulin exposure in non–small cell lung cancer Invited Reviewed International journal

2021.5

Osimertinib Versus Osimertinib Plus Chemotherapy for Non-Small Cell Lung Cancer with EGFR (T790M)-Associated Resistance to Initial EGFR Inhibitor Treatment: An Open-Label, Randomized Phase 2 Clinical Trial Invited Reviewed International journal

Tanaka K., Asahina H., Kishimoto J., Miyata Y, Uchida T., Watanabe K., Hamai K., Harada T., Tsubata Y., Sugawara S., Kobayashi K., Sugio K., Oisumi S. & Okamoto I.

European Journal of Cancer   2021.5

Phase 3 Trial Comparing Nanoparticle Albumin-Bound Paclitaxel With Docetaxel for Previously Treated Advanced NSCLC Reviewed International journal

Yoneshima Y, Morita S, Ando M, Nakamura A, Iwasawa S, Yoshioka H, Goto Y, Takeshita M, Harada T, Hirano K, Oguri T, Kondo M, Miura S, Hosomi Y, Kato T, Kubo T, Kishimoto J, Yamamoto N, Nakanishi Y, Okamoto I

Journal of Thoracic Oncology   2021.4

A Phase II Study of Osimertinib Combined With Platinum Plus Pemetrexed in Patients With EGFR-Mutated Advanced NoneSmall-cell Lung Cancer: The OPAL Study (NEJ032C/LOGIK1801) Invited Reviewed International journal

Asahina H., Tanaka K., Morita S., Maemondo M., Seike M., Okamoto I., Oizumi S., Kagamu H., Takahashi K., Kikuchi T., Isobe T., Sugio K. & Kobayashi K.

Clinical Lung Cancer   2021.3

Phase 2 Study of Nimotuzumab in Combination With Concurrent Chemoradiotherapy in Patients With Locally Advanced NoneSmall-Cell Lung Cancer Invited Reviewed International journal

Yamamoto N., Harada H., Okamoto I., Masuda N.., Hayakawa K, Satouchi M., Soejima T., Nishio M., Kozuka T., Takeda K., Tanaka M., Seto T., Sasaki T., Tsubouchi H., Kakurai Y., Nishimura Y. & Nakagawa K.

Clinical Lung Cancer   2021.3

Clinical utility of pretreatment Glasgow prognostic score in non-small-cell lung cancer patients treated with immune checkpoint inhibitors Invited Reviewed International journal

Takamori S., Takada K., Shimokawa M., Matsubara T., Fujishita T., Ito K., Toyozawa R., Yamaguchi M., Okamoto T., Yoneshima Y., Tanaka K., Okamoto I., Tagawa T. & Mori M.

Lung Cancer   2021.2

Continuous monitoring of neutrophils to lymphocytes ratio for estimation of onset and severity of immune-related adverse events and prognosis Invited Reviewed International journal

Matsukane R., Watanabe H.., Minami H, Hata K., Suetsugu K., Tsuji T., Masuda S., Okamoto I., Nakagawa T., Ito T., Eto M., Mori M., Nakanishi Y. & Egashira N.

Scientific Reports   2021.1

Predicting osimertinib-treatment outcomes through EGFR mutant-fraction monitoring in the circulating tumor DNA of EGFR T790M-positive patients with non-small cell lung cancer (WJOG8815L). Invited Reviewed International journal

Sakai K., Takahama T., Shimokawa M., Azuma K., Takeda M., Kato T., Daga H., Okamoto I., Akamatsu H., Teraoka S., Ono A., Ohira T., Yokoyama T., Yamamoto N., Nakagawa K. & Nishio K.

Molecular Oncology   2021.1

Erlotinib plus bevacizumab vs erlotinib monotherapy as first-line treatment for advanced EGFR mutation-positive non-squamous non-small-cell lung cancer: Survival follow-up results of the randomized JO25567 study Invited Reviewed International journal

Yamamoto N., Seto T., Nishio M., Goto K., Yamamoto N., Okamoto I., Yamanaka T., Tanaka M., Takahashi K. & Fukuoka M.

Lung Cancer   2021.1

Differential significance of molecular subtypes which were classified into EGFR exon 19 deletion on the first line afatinib monotherapy Invited Reviewed International journal

Tokudome N., Koh Y., Akamatsu H., Fujimoto D., Okamoto I., Nakagawa K., Hida T., Imamura F., Morita S. & Yamamoto N.

BMC Cancer   2020.12

A Phase II Study of Osimertinib for Patients with Radiotherapy-naïve CNS Metastasis of Non-Small Cell Lung Cancer: Treatment Rationale and Protocol Design of the　OCEAN Study (LOGIK 1603/WJOG 9116L) Invited Reviewed International journal

2020.12

Nivolumab treatment of elderly Japanese patients with non-small cell lung cancer: subanalysis of a real-world retrospective observational study. Invited Reviewed International journal

Okishio K., Morita R., Shimizu J., Saito H., Sakai H., Kim YH., Hataji O., Yomota M., Nishio M., Aoe K., Kanai O., Kumagai T., Kibata K., Tsukamoto H., Oizumi S., Fujimoto D., Tanaka H., Mizuno K., Masuda T., Kozuki T., Haku T., Suzuki H., Okamoto I., Hoshiyama H., Yada N. & Ohe Y.

ESMO Open   2020.12

First-line pembrolizumab vs chemotherapy in metastatic non-small-cell lung cancer: KEYNOTE-024 Japan subset. Invited Reviewed International journal

Satouchi M., Nosaki K., Takahashi T., Nakagawa K., Aoe K., Kurata T., Sekine A., Horiike A., Fukuhara T., Sugawara S., Umemura S., Saka H., Okamoto I., Yamamoto N., Sakai H., Kishi K., Katakami N., Horinouchi H., Hida T., Okamoto H., Atagi S., Ohira T., Han SR., Noguchi K., Ebiana V. & Hotta K.

Cancer Science   2020.12

A phase 2 study of atezolizumab for pretreated non-small cell lung cancer with idiopathic interstitial pneumonitis Invited Reviewed International journal

Ikeda S., Kato T., Kenmotsu H., Ogura T., Iwasawa S., Sato Y., Harada T., Kubota K., Tokito T., Okamoto I., Furuya N., Yokoyama T., Hosokawa S., Iwasawa T., Yamanaka T. & Okamoto H.

Journal of Thoracic Oncology   2020.12

Integrated Immunohistochemical Study on Small-Cell Carcinoma of the Lung Focusing on Transcription and Co-Transcription Factors Invited Reviewed International journal

Sato Y., Okamoto I., Kameyama H., Kudoh S., Saito H., Sanada M., Kudo N., Wakimoto J., Fujino K., Ikematsu Y., Tanaka K., Nishikawa A., Sakaguchi R. & Ito T.

Diagnostics   2020.11

Association of Mps one binder kinase activator 1(MOB1) expression with poor disease-survival in individuals with non-small cell lung cancer. Invited Reviewed International journal

Ando N., Tanaka K., Otsubo K., Toyokawa G., Ikematsu Y., Ide M., Yoneshima Y., Iwama E., Inoue H., Ijichi K., Tagawa T., Nakanishi Y. & Okamoto I.

Thoracic Cancer   2020.10

Predictive and prognostic impact of primary tumor-bearing lobe in non-small cell lung cancer patients treated with anti-PD-1 therapy Invited Reviewed International journal

Takamori S., Takada K., Shimokawa M., Matsubara T., Haratake N., Miura N., Toyozawa R., Yamaguchi M., Takenoyama M., Yoneshima Y, Tanaka K., Okamoto I., Tagawa T. & Mori M.

International Journal of Cancer   2020.10

Expression of PD-L1, PD-L2, and IDO1 on tumor cells and density of CD8-positive tumor-infiltrating lymphocytes in early-stage lung adenocarcinoma according to histological subtype Invited Reviewed International journal

Takada K., Toyokawa G., Kinoshita F., Jogo T., Kohashi K., Wakasu S., Ono Y., Tanaka K., Oba T., Osoegawa A., Tagawa T., Azuma K., Okamoto I., Shimokawa M., Oda Y. & Mori M.

Journal of Cancer Research and Clinical Oncology   2020.10

A Randomized, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients With Metastatic Squamous Non–Small-Cell Lung Invited Reviewed International journal

2020.10

Treatment Rationale and Design for APPLE (WJOG11218L): A Multicenter, Open-Label, Randomized Phase 3 Study of Atezolizumab and Platinum/Pemetrexed With or Without Bevacizumab for Patients With Advanced Nonsquamous Non–Small-Cell Lung Cancer. Invited Reviewed International journal

2020.9

A Randomized Phase III Study of Maintenance Therapy with　S-1 Plus Best Supportive Care Versus Best Supportive Care　After Induction Therapy with Carboplatin Plus S-1 for Advanced or Relapsed Squamous Cell Carcinoma of the Lung　(WJOG7512L) Invited Reviewed International journal

2020.8

NEUROD1 is highly expressed in extensive-stage small cell lung cancer and promotes tumor cell migration. Invited Reviewed International journal

Ikematsu Y., Tanaka K., Toyokawa G., Ijichi K., Ando N., Yoneshima Y., Iwama E., Inoue H., Tagawa T., Nakanishi Y. & Okamoto I.

Lung Cancer   2020.8

Survival and Prognostic Factors in Elderly Patients Receiving Second-line Chemotherapy for Relapsed Small-Cell Lung Cancer: Results from the Japanese Joint Committee of Lung Cancer Registry Invited Reviewed International journal

Igawa S., Naoki K., Shintani Y., Sekine I., Shukuya T., Takayama K., Inoue A., Okamoto I., Kiura K., Takahashi K., Yamamoto N., Takiguchi Y., Miyaoka E., Okumura M. & Yoshino I.

Lung Cancer   2020.8

Key prognostic factors for EGFR-mutated non-adenocarcinoma lung cancer patients in the Japanese Joint Committee of Lung Cancer Registry Database Invited Reviewed International journal

Kobayashi K., Soejima K., Fukunaga K., Shintani Y., Sekine I., Shukuya T., Takayama K., Inoue A., Okamoto I., Kiura K., Takahashi K., Yamamoto N., Takiguchi Y., Miyaoka E., Okumura M. & Yoshino I.

Lung Cancer   2020.8

Immune-checkpoint profiles for T cells in bronchoalveolar lavage fluid of patients with immune-checkpoint inhibitorrelated interstitial lung disease Invited Reviewed International journal

Suzuki K., Yanagihara T., Matsumoto K., Kusaba H., Yamaguchi T., Ikematsu Y., Tanaka K., Otsubo K., Inoue H., Yoneshima Y, Iwama E., Arimura-Omori M., Harada E., Hamada N., Okamoto I. & Nakanishi Y.

International Immunology   2020.8

Phase I safety and pharmacokinetic study of YM155, a potent selective survivin inhibitor, in combination with erlotinib in patients with EGFR TKI refractory advanced non-small-cell lung cancer Invited Reviewed International journal

Shimizu T., Nishio K., Sakai K., Okamoto I., Okamoto K., Takeda M., Morishima M. & Nakagawa K.

Cancer Chemotherapy and Pharmacology   2020.8

Paired genetic analysis by next-generation sequencing of lung cancer and associated idiopathic pulmonary fibrosis Invited Reviewed International journal

Otsubo K., Iwama E., Ijichi K., Kubo N., Yoneshima Y., Inoue H., Tanaka K., Osoegawa A., Tagawa T., Nakanishi Y. & Okamoto I.

Cancer Science   2020.7

Randomized Phase III Study of Cisplatin Plus Pemetrexed Versus Cisplatin Plus Vinorelbine for Completely Resected Stage II to IIIA Nonsquamous Non–Small-Cell Lung Cancer Invited Reviewed International journal

2020.7

Serum markers associated with treatment 1 response and survival in non-small cell lung cancer patients treated with anti-PD-1 therapy Invited Reviewed International journal

Takada K., Takamori S., Yoneshima Y., Tanaka K., Okamoto I., Shimokawa M., Osoegawa A., Tagawa T., Oda Y., Nakanishi Y. & Mori M.

Lung Cancer   2020.7

Updated Survival Data for a Phase I/II Study of Carboplatin plus Nab-Paclitaxel and Concurrent Radiotherapy in Patients with Locally Advanced Non-Small Cell Lung Cancer. Invited Reviewed International journal

Tsuchiya-Kawano Y., Sasaki T., Yamaguchi H., Hirano K., Horiike A., Satouchi M., Hosokawa S., Morinaga R., Komiya K., Inoue K., Fujita Y., Toyozawa R., Kimura T., Takahashi K., Nishikawa K., Kishimoto J., Nakanishi Y. & Okamoto I.

The Oncologist   2020.6

A Japanese lung cancer registry study on demographics and treatment modalities in medically treated patients Invited Reviewed International journal

Sekine I., Shintani Y., Shukuya T., Takayama K., Inoue A., Okamoto I., Kiura K., Takahashi K., Dosaka-Akita H., Takiguchi Y., Miyaoka E., Okumura M. & Yoshino I.

Cancer Science   2020.5

Clinical impact of skeletal muscle area in patients with non‑small cell lung cancer treated with anti‑PD‑1 inhibitors Invited Reviewed International journal

2020.5

Plasma screening for the T790M mutation of EGFR and phase II study of osimertinib efficacy in plasma T790M–positive non–small cell lung cancer: West Japan Oncology Group (WJOG) 8815L/LPS study. Invited Reviewed International journal

2020.5

Survival Analysis for Patients with ALK Rearrangement-Positive Non-Small Cell Lung Cancer and a Poor Performance Status Treated with Alectinib: Updated Results of Lung Oncology Group in Kyushu 1401. Invited Reviewed International journal

Iwama E., Goto Y., Murakami H., Tsumura S., Sakashita H., Mori Y., Nakagaki N., Fujita Y., Seike M., Bessho A., Ono M., Nishitsuji M., Akamatsu H., Morinaga R., Akagi T., Shimose T., Tokunaga S., Yamamoto N., Nakanishi Y., Sugio K. & Okamoto I.

The Oncologist   2020.4

Randomized Phase III Study of Continuation Maintenance Bevacizumab With or Without Pemetrexed in Advanced Nonsquamous Non-Small-Cell Lung Cancer: COMPASS (WJOG5610L). Invited Reviewed International journal

Seto T., Azuma K., Yamanaka T., Sugawara S., Yoshioka H., Wakuda K., Atagi S., Iwamoto Y., Hayashi H., Okamoto I., Saka H., Mitsuoka S., Fujimoto D., Nishino K., Horiike A., Daga H., Sone T., Yamamoto N., Nakagawa K. & Nakanishi Y.

Journal of Clinical Oncology   2020.3

Design and Rationale for a Phase III, Randomized, Placebo-controlled Trial of Durvalumab With or Without Tremelimumab After Concurrent Chemoradiotherapy for Patients With Limited-stage Small-cell Lung Cancer: The ADRIATIC Study. Invited Reviewed International journal

Senan S., Okamoto I., Lee GW., Chen Y., Niho S., Mak G., Yao W., Shire N., Jiang H. & Cho BC.

Clinical Lung Cancer   2020.3

Real-world effectiveness and safety of nivolumab in patients with non-small cell lung cancer: A multicenter retrospective observational study in Japan. Invited Reviewed International journal

Morita R., Okishio K., Shimizu J., Saito H., Sakai H., Kim YH., Hataji O., Yomota M., Nishio M., Aoe K., Kanai O., Kumagai T., Kibata K., Tsukamoto H., Oizumi S., Fujimoto D., Tanaka H., Mizuno K., Masuda T., Kozuki T., Haku T., Suzuki H., Okamoto I., Hoshiyama H., Ueda J. & Ohe Y.

Lung Cancer   2020.2

Therapies after first-line afatinib in patients with EGFRm+ NSCLC in Japan: retrospective analysis of LUX-Lung 3. Invited Reviewed International journal

Yoshioka H., Kato T., Okamoto I., Tanaka H., Hida T., Seto T., Kiura K., Tian Y., Azuma H. & Yamamoto N.

Future Oncology   2020.2

Longitudinal monitoring of somatic genetic alterations in circulating cell-free DNA during treatment with epidermal growth factor receptor-tyrosine kinase inhibitors. Invited Reviewed International journal

Iwama E., Sakai K., Hidaka N., Inoue K., Fujii A., Nakagaki N., Ota K., Toyozawa R., Azuma K., Nakatomi K., Harada T., Hisasue J., Sakata S., Shimose T., Kishimoto J., Nakanishi Y., Nishio K. & Okamoto I.

Cancer   2020.1

Immune checkpoint protein and cytokine expression by T lymphocytes in pleural effusion of cancer patients receiving anti-PD-1 therapy. Invited Reviewed International journal

Ikematsu Y., Tanaka K., Yanagihara T., Liu R., Inoue H., Yoneshima Y., Ota K., Iwama E., Takata S., Hata K., Takahata Y., Wataya H., Nakanishi Y. & Okamoto I.

Lung Cancer   2019.12

Design and Rationale for a Phase III, Randomized, Placebo-controlled Trial of Durvalumab With or Without Tremelimumab After Concurrent Chemoradiotherapy for Patients With Limited-stage Small-cell Lung Cancer: The ADRIATIC Study. Invited Reviewed International journal

Senan S., Okamoto I., Lee GW., Chen Y., Niho S., Mak G., Yao W., Shire N., Jiang H. & Cho BC.

Clinical Lung Cancer   2019.12

Final overall survival results of WJTOG3405, a randomized phase III trial comparing gefitinib versus cisplatin with docetaxel as the first-line treatment for patients with stage IIIB/IV or postoperative recurrent EGFR mutation-positive non-small-cell lung cancer. Invited Reviewed International journal

Yoshioka H., Shimokawa M., Seto T., Morita S., Yatabe Y., Okamoto I., Tsurutani J., Satouchi M., Hirashima T., Atagi S., Shibata K., Saito H., Toyooka S., Yamamoto N., Nakagawa K. & Mitsudomi T.

Annals of Oncology   2019.12

Tissue and Plasma EGFR Mutation Analysis in the FLAURA Trial: Osimertinib versus Comparator EGFR Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer. Invited Reviewed International journal

Gray JE., Okamoto I., Sriuranpong V., Vansteenkiste J., Imamura F., Lee JS., Pang YK., Cobo M., Kasahara K., Cheng Y., Nogami N., Cho EK., Su WC., Zhang G., Huang X., Li-Sucholeiki X., Lentrichia B., Dearden S., Jenkins S., Saggese M., Rukazenkov Y. & Ramalingam SS.

Clinical Cancer Research   2019.11

Phase I safety and pharmacokinetics study of rovalpituzumab tesirine in Japanese patients with advanced, recurrent small cell lung cancer. Invited Reviewed International journal

Udagawa H., Akamatsu H., Tanaka K., Takeda M., Kanda S., Kirita K., Teraoka S., Nakagawa K., Fujiwara Y., Yasuda I., Okubo S., Shintani M., Kosloski MP., Scripture C., Tamura T. & Okamoto I.

Lung Cancer   2019.9

Osimertinib for Japanese patients with T790M-positive advanced non-small-cell lung cancer: A pooled subgroup analysis. Invited Reviewed International journal

Hirashima T., Satouchi M., Hida T., Nishio M., Kato T., Sakai H., Imamura F., Kiura K., Okamoto I., Kasahara K., Uchida H., Vowler SL. & Mitsudomi T.

Cancer Science   2019.9

Genetic Profiling of Non–Small Cell Lung Cancer at Development of Resistance to First- or Second-Generation EGFR-TKIs by CAPP-Seq Analysis of Circulating Tumor DNA Invited Reviewed International journal

24 ( ８ )   1022 - 1026   2019.8

Subgroup Analysis of Japanese Patients in a Phase III Study of Atezolizumab in Extensive-stage Small-cell Lung Cancer (IMpower133). Invited Reviewed International journal

Nishio M., Sugawara S., Atagi S., Akamatsu H., Sakai H., Okamoto I., Takayama K., Hayashi H., Nakagawa Y. & Kawakami T.

Clinical Lung Cancer   2019.7

Randomized phase II study of pemetrexed or pemetrexed plus bevacizumab for elderly patients with previously untreated non-squamous non-small cell lung cancer Invited Reviewed International journal

Fukuda M., Kitazaki T., Ogawara D., Ichiki M., Mukae H., Riichiroh Maruyama, Nakagaki N., Shimada M., Ikeda T., Kishimoto J., Harada T., Seto T., Ebi N., Takayama K., Okamoto I., Ichinose Y. & Sugio K.

Lung Cancer   2019.6

A clinicopathological and prognostic analysis of PD-L2 expression in surgically resected primary lung squamous cell carcinoma Invited Reviewed International journal

Matsubara T., Takada K., Azuma K., Takamori S., Toyokawa G., Haro A., Osoegawa A., Tagawa T., Kawahara A., Akiba J., Okamoto I., Nakanishi Y., Oda Y., Hoshino T. & Maehara Y.

Annals of Surgical Oncology   2019.6

Prognostic Impact of Programmed Death-Ligand 2 Expression in Primary Lung Adenocarcinoma Patients. Invited Reviewed International journal

Takamori S., Takada K., Azuma K., Jogo Y., Shimokawa M., Toyokawa G., Hirai F., Tagawa T., Kawahara A, Akiba J, Okamoto I., Nakanishi Y., Oda Y. Hoshino T & Maehara Y.

Annals of Surgical Oncology   2019.6

Association between peripheral blood markers and immune-related factors on tumor cells in patients with resected primary lung adenocarcinoma. Invited Reviewed International journal

Takada K., Shimokawa M., Tanaka K., Kohashi K., Haro A., Osoegawa A., Tagawa T., Azuma K., Okamoto I., Oda Y. & Mori M.

PLoS One   2019.6

Clinical significance of monitoring EGFR mutation in plasma using multiplexed digital PCR in EGFR mutated patients treated with afatinib (West Japan Oncology Group 8114LTR study) Invited Reviewed International journal

2019.5

Japanese Subgroup Analysis of a Phase III Study of S-1 versus Docetaxel in Non-Small Cell Lung Cancer Patients After Platinum-Based Treatment: EAST-LC Identification of Genomic Alterations Acquired During Treatment with EGFR-TKIs in Non-small Cell Lung Cancer Invited Reviewed International journal

Sugawara S., Nakagawa K., Yamamoto N., Nokihara H., Ohe Y., Nishio M., Takahashi T., Goto K., Maemondo M., Ichinose Y., Seto T., Sakai H., Gemma A., Imamura F., Shingyoji M., Saka H., Inoue A., Takeda K., Okamoto I., Kiura K., Morita S. & Tomohide Tamura T.*

International Journal of Clinical Oncology   2019.5

Safety and efficacy of PD-1 inhibitors in non–small cell lung cancer patients positive for antinuclear antibodies Invited Reviewed International journal

2019.4

Updated Survival Data for a Phase I/II Study of Carboplatin plus Nab-Paclitaxel and Concurrent Radiotherapy in Patients with Locally Advanced Non-Small Cell Lung Cancer. Invited Reviewed International journal

Tsuchiya-Kawano Y., Sasaki T., Yamaguchi H., Hirano K., Horiike A., Satouchi M., Hosokawa S., Morinaga R., Komiya K., Inoue K., Fujita Y., Toyozawa R., Kimura T., Takahashi K., Nishikawa K., Kishimoto J., Nakanishi Y. & Okamoto I.

The Oncologist   2019.4

Identification of Genomic Alterations Acquired During Treatment with EGFR-TKIs in Non-small Cell Lung Cancer Invited Reviewed International journal

Kubo N., Harada T., Shiraishi Y., Nosaki K., Nakagaki N., Takeshita M., Ouchi H., Iwama E., Tanaka K., Okamoto I., Sasaki H. & Nakanishi Y.

Anticancer Research   2019.2

Heregulin expression and its clinical implication for patients with EGFR-mutant non-small cell lung cancer treated with EGFR-tyrosine kinase inhibitors. Invited Reviewed International journal

Yonesaka K., Iwama E., Hayashi H., Suzuki S., Kato R., Watanabe S., Takahama T., Tanizaki J., Tanaka K., Takeda M., Sakai K., Azuma K., Chiba Y., Atagi S., Nishio K., Okamoto I. & Nakagawa K.

Scientific Reports   2019.1

Pemetrexed and carboplatin combination therapy followed by pemetrexed maintenance in Japanese patients with non-squamous non-small cell lung cancer: A subgroup analysis of elderly patients. Invited Reviewed International journal

Nogami N., Nishio M., Okamoto I., Enatsu S., Suzukawa K., Takai H., Nakagawa K. & Tamura T.

Respiratory Investigation   2019.1

Osimertinib versus standard-of-care EGFR-TKI as first-line treatment in patients with EGFRm advanced NSCLC: FLAURA Asian subset. Invited Reviewed International journal

Cho BC., Chewaskulyong B., Lee KH., Dechaphunkul A., Sriuranpong V., Imamura F., Nogami N., Kurata T., Okamoto I., Zhou C., Cheng Y., Cho EK., Voon PJ., Lee JS., Mann H., Saggese M., Reungwetwattana T., Ramalingam SS. & Ohe Y.

Journal of Thoracic Oncology   2019.1

Osimertinib versus standard-of-care EGFR-TKI as first-line treatment for EGFRm advanced NSCLC: FLAURA Japanese subset Invited Reviewed International journal

Ohe Y., Imamura F., Nogami N., Okamoto I., Kurata T., Terufumi Kato T., Sugawara S., Ramalingam SS., Uchida H., Hodge R., Vowler SL., Walding A & Nakagawa K

Japanese Journal of Clinical Oncology   2019.1

18F-FDG uptake in PET/CT is a potential predictive biomarker of response to anti-PD-1 antibody therapy in non-small cell lung cancer. Invited Reviewed International journal

Takada K., Toyokawa G., Yoneshima Y., Tanaka K., Okamoto I., Shimokawa M., Wakasu S., Haro A., Osoegawa A., Tagawa T., Oda Y., Nakanishi Y. & Mori M.

Scientific Reports   2019.1

Association of nephrotoxicity during platinum-etoposide doublet therapy with UGT1A1 polymorphisms in small cell lung cancer patients Invited Reviewed International journal

Anai S., Iwama E., Yoneshima Y., Otsubo K., Tanaka K., Nakanishi Y. & Okamoto I.

Lung Cancer   126   156 - 161   2018.12

CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. Invited Reviewed International journal

Reungwetwattana T., Nakagawa K., Cho BC., Cobo M., Cho EK., Bertolini A., Bohnet S., Zhou C., Lee KH., Nogami N., Okamoto I., Leighl N., Hodge R., McKeown A., Brown AP., Rukazenkov Y., Ramalingam SS. & Vansteenkiste J.

Journal of Clinical Oncology   36 ( 33 )   3290 - 3297   2018.11

Phase I/II study of carboplatin plus nab-paclitaxel and concurrent radiotherapy for patients with locally advanced non–small cell lung cancer Invited Reviewed International journal

Kawano Y., Sasaki T., Yamaguchi H., Hirano K., Horiike A., Satouchi M., Hosokawa S., Morinaga R., Komiya k., Inoue K., Fujita Y., Toyozawa R., Kimura T., Takahashi K.,Nishikawa K.,Kishimoto J., Nakanishi Y. & 　Okamoto I.

125   136 - 141   2018.11

Sensitivity of epidermal growth factor receptor with single or double uncommon mutations to afatinib confirmed by a visual assay. Invited Reviewed International journal

Kimura S., Tanaka K., Harada T., Liu R., Shibahara D., Kawano Y., Nakanishi Y. & Okamoto I.

Cancer Science   109 ( 11 )   3657 - 3661   2018.11

Intrinsic and Extrinsic Regulation of PD-L2 Expression in Oncogene-Driven Non-Small Cell Lung Cancer. Invited Reviewed International journal

Shibahara D., Tanaka K., Iwama E., Kubo N., Ota K., Azuma K., Harada T., Fujita J. Nakanishi Y. & Okamoto I.

Journal of Thoracic Oncology   13 ( 7 )   926 - 937   2018.7

Detection of identical T cell clones in peritumoral pleural effusion and pneumonitis lesions in a cancer patient during immune-checkpoint blockade. Invited Reviewed International journal

Tanaka K., Yanagihara T., Ikematsu Y., Inoue H., Ota K., Kashiwagi E., Suzuki K., Hamada N., Takeuchi A., Tatsugami K., Eto M., Ijichi K., Oda Y., Otsubo K., Yoneshima Y., Iwama E., Nakanishi Y. & Okamoto I.

Oncotarget   9 ( 55 )   30587 - 30593   2018.7

Osimertinib in Japanese patients with EGFR T790M mutation-positive advanced non-small-cell lung cancer: AURA3 trial. Invited Reviewed International journal

Akamatsu H., Katakami N., Okamoto I., Kato T., Kim YH., Imamura F., Shinkai M., Hodge RA., Uchida H. & Hida T.

Cancer Science   109 ( 6 )   1930 - 1938   2018.6

Expression of brain-derived neurotrophic factor and its receptor TrkB is associated with poor prognosis and a malignant phenotype in small cell lung cancer. Invited Reviewed International journal

Kimura S., Harada T., Ijichi K., Tanaka K., Liu R., Shibahara D., Kawano Y., Otsubo K., Yoneshima Y., Iwama E., Nakanishi Y. & Okamoto I.

Lung Cancer   120   98 - 107   2018.6

PD-L1 expression in lung adenocarcinoma harboring EGFR mutations or ALK rearrangements. Invited Reviewed International journal

Yoneshima Y., Ijichi K., Anai S., Ota K., Otsubo K., Iwama E., Tanaka K., Oda Y., Nakanishi Y. & Okamoto I.

Lung Cancer   118   36 - 40   2018.4

Exploration of resistance mechanisms for EGFR-TKIs based on plasma analysis by digital PCR and next-generation sequencing. Invited Reviewed International journal

Iwama E., Sakai K., Azuma K., Harada D., Nosaki K., Hotta K., Nishio M., Kurata T., Fukuhara T., Akamatsu H., Goto K., Shimose T., Kishimoto J., Nakanishi Y., Nishio K. & Okamoto I.

Cancer Science   109   3921 - 3933   2018.4

Clinical Significance of PD-L1 Expression in Brain Metastases from Non-small Cell Lung Cancer. Invited Reviewed International journal

Takamori S., Toyokawa G., Okamoto I., Takada K, Kinoshita F., Kozuma Y., Matsubara T., Haratake N., Akamine T., Mukae N., Hirai F., Tagawa T., Oda Y., Iwaki T., Iihara K., Nakanishi Y. & Maehara Y.

Anticancer Research   38 ( 1 )   553 - 557   2018.4

Heterogeneous distribution of alectinib in neuroblastoma xenografts revealed by matrix-assisted laser desorption ionisation mass spectrometry imaging: A pilot study. Invited Reviewed International journal

Ryu S., Hayashi M., Aikawa H., Okamoto I., Fujiwara Y & Hamada A.

British Journal of Pharmacology   2018.4

Osimertinib in patients with epidermal growth factor receptor T790M advanced non-small cell lung cancer selected using cytology samples. Invited Reviewed International journal

Kiura K., Yoh K., Katakami N., Nogami N., Kasahara K., Takahashi T., Okamoto I., Cantarini M., Hodge R. & Uchida H.

Cancer Science   2018.4

Prognostic impact of programmed death-ligand 2 expression in primary lung adenocarcinoma patients Invited Reviewed International journal

Takamori S., Takada K., Azuma K., Jogo T., Shimokawa M., Toyokawa G., Hirai F., Tagawa T., Kawahara A., Akiba J., Okamoto I., Nakanishi Y., Oda Y., Hoshino T. & Maehara Y.

Annals of Surgical Oncology   2018.4

Phase 3 study of ceritinib vs chemotherapy in ALK-rearranged NSCLC patients previously treated with chemotherapy and crizotinib (ASCEND-5): Japanese subset. Invited Reviewed International journal

Kiura K., Imamura F., Kagamu H., Matsumoto S., Hida T., Nakagawa K., Satouchi M., Okamoto I., Takenoyama M., Fujisaka Y., Kurata T., Ito M., Tokushige K., Hatano B. & Nishio M.

Japanese Journal of Clinical Oncology   2018.4

PD-L2 Expression as a Potential Predictive Biomarker for the Response to Anti-PD-1 Drugs in Patients with Non-small Cell Lung Cancer. Invited Reviewed International journal

Takamori S., Takada .K, Toyokawa G., Azuma K., Shimokawa M., Jogo T., Yamada Y., Hirai F., Tagawa T., Kawahara A., Akiba J., Okamoto I., Nakanishi Y., Oda Y., Hoshino T. & Maehara Y.

Anticancer Rsearch   2018.4

Prognostic Impact of PD-L2 Expression and Association with PD-L1 in Patients with Small-cell Lung Cancer. Invited Reviewed International journal

Takamori S., Takada K., Azuma K., Jogo Y., Kinoshita F., Kozuma Y., Matsubara T., Haratake N., Akamine T., Toyokawa G., Hirai F., Tagawa T., Okamoto I., Nakanishi Y., Kawahara A., Akiba J., Oda Y. & Maehara Y.

Anticancer Research   2018.4

Association of preoperative serum CRP with PD-L1 expression in 508 patients with non-small cell lung cancer: A comprehensive analysis of systemic inflammatory markers. Invited Reviewed International journal

Akamine T., Takada K., Toyokawa G., Kinoshita F., Matsubara T., Kozuma Y., Haratake N., Takamori S., Hirai F., Tagawa T., Okamoto T., Yoneshima Y., Okamoto I., Shimokawa M., Oda Y., Nakanishi Y. & Maehara Y.

Journal of Surgical Oncology   2018.3

Real world treatment and outcomes in EGFR mutation-positive non-small cell lung cancer: Long-term follow-up of a large patient cohort. Invited Reviewed International journal

Okamoto I., Morita S., Tashiro N., Imamura F., Inoue A., Seto T., Yamamoto N., Ohe Y., Nakagawa K. & Fukuoka M.

Lung Cancer   117   14 - 19   2018.3

Erlotinib plus bevacizumab phase ll study in patients with advanced non-small-cell lung cancer (JO25567): extended safety follow-up Invited Reviewed International journal

Kato T., Seto T., Nishio M., Goto K., Yamamoto N., Okamoto I., Tai L., Yu W., Khaznadar T., Tajima K., Shibata M., Seki A. & Yamamoto N.

Drug Safety   2018.2

Prediction of Therapeutic Effect of Chemotherapy for NSCLC Using Dual-Input Perfusion CT Analysis: Comparison among Bevacizumab Treatment, Two-Agent Platinum-based Therapy without Bevacizumab, and Other Non-Bevacizumab Treatment Groups. Invited Reviewed International journal

Yabuuchi H., Kawanami S., Iwama E., Okamoto I., Kamitani T., Sagiyama K., Yamasaki Y. & Honda H.

Radiology   2018.2

Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. Invited Reviewed International journal

184. Soria JC., Ohe Y., Vansteenkiste J., Reungwetwattana T., Chewaskulyong B., Lee KH., Dechaphunkul A., Imamura F., Nogami N., Kurata T., Okamoto I., Zhou C., Cho BC., Cheng Y., Cho EK., Voon PJ., Planchard D., Su WC., Gray JE., Lee SM., Hodge R., Marotti M., Rukazenkov Y., Ramalingam SS.; FLAURA

New England Journal of Medicine   378 ( 2 )   113 - 125   2018.1

Prevalence of Delta-like protein 3 expression in patients with small cell lung cancer. Invited Reviewed International journal

Tanaka K., Isse K., Fujihira T., Takenoyama M,. Saunders L., Bheddah S., Nakanishi Y. & Okamoto I.

Lung Cancer   115   116 - 120   2018.1

Treatment rationale and design for J-SONIC: a randomized study of carboplatin plus nab-paclitaxel with or without nintedanib for advanced non–small cell lung cancer with idiopathic pulmonary fibrosis Invited Reviewed International journal

19 ( 1 )   e5 - e9   2018.1

Alectinib for patients with ALK rearrangement-positive non-small cell lung cancer and a poor performance status (Lung Oncology Group in Kyushu 1401) Invited Reviewed International journal

Iwama E., Goto Y., Murakami H., Harada T., Tsumura S., Sakashita H., Mori Y., Nakagaki N., Fujita Y., Seike M., Bessho A., Ono M., Okazaki A., Akamatsu H., Morinaga R., Ushijima S., Shimose T., Tokunaga S., Hamada H., Yamamoto N., Nakanishi Y., Sugio K. & Okamoto I.*

Journal of Thoracic Oncology   1161- - 1166   2017.12

CD44 variant–dependent regulation of redox balance in EGFR mutation–positive non–small cell lung cancer: A target for treatment Reviewed International journal

72 - 78   2017.11

Erlotinib plus bevacizumab phase ll study in patients with advanced non-small-cell lung cancer (JO25567): extended safety follow-up Invited Reviewed International journal

Kato T.*, Seto T., Nishio M., Goto K., Yamamoto N., Okamoto I., Tai L., Yu W., Khaznadar T., Tajima K., Shibata M., Seki A. & Yamamoto N.

Drug Safety   2017.10

Prediction of Therapeutic Effect of Chemotherapy for NSCLC Using Dual-Input Perfusion CT Analysis: Comparison among Bevacizumab Treatment, Two-Agent Platinum-based Therapy without Bevacizumab, and Other Non-Bevacizumab Treatment Groups. Reviewed International journal

Yabuuchi H.*, Kawanami S., Iwama E., Okamoto I., Kamitani T., Sagiyama K., Yamasaki Y. & Honda H.

Radiology   2017.10

Heterogeneous distribution of alectinib in neuroblastoma xenografts revealed by matrix-assisted laser desorption ionisation mass spectrometry imaging: A pilot study. Invited Reviewed International journal

Ryu S., Hayashi M., Aikawa H., Okamoto I., Fujiwara Y & Hamada A.*

British Journal of Pharmacology   2017.10

Ota K., Harada T.*, Otsubo K., Fujii A., Tsuchiya Y., Tanaka K., Okamoto I. & Nakanishi Y. Reviewed International journal

Visualization and quantitation of epidermal growth factor receptor homodimerization and activation with a proximity ligation assay

Oncotarget   8 ( 42 )   72127 - 72132   2017.9

Phase I study of salazosulfapyridine in combination with cisplatin and pemetrexed for advanced non–small cell lung cancer Invited Reviewed International journal

108 ( 9 )   1843 - 1849   2017.9

Acquisition of the T790M resistance mutation during afatinib treatment in EGFR tyrosine kinase inhibitor–naïve patients with non–small cell lung cancer harboring EGFR mutation. Reviewed International journal

8 ( 40 )   68123 - 68130   2017.9

Tumor-infiltrating lymphocyte-mediated pleuritis followed by marked shrinkage of metastatic kidney cancer of the chest wall during nivolumab treatment Invited Reviewed International journal

Yanagihara T., Tanaka K., Ota K., Kashiwagi E., Takeuchi A., Tatsugami K, Eto M, Nakanishi Y. & Okamoto I.*

Annals of Oncology 28(8)   2038 - 2039   2017.8

Discrepancy in Programmed Cell Death-Ligand 1 Between Primary and Metastatic Non-Small-Cell Lung Cancer. ANTICANCER RESEARCH 37(8), 4223-4228 (2017) Invited Reviewed International journal

17. Takamori S, Toyokawa G*, Okamoto I, Takada K, Kozuma Y, Matsubara T, Haratake N, Akamine T, Katsura M, Mukae N, Shoji F, Okamoto T, Oda Y, Iwaki T, Iihara K, Nakanishi Y, Maehara Y.

ANTICANCER RESEARCH 37(8)   4223- - 4228 (2017)   2017.8

Marked response to pembrolizumab in a patient with pulmonary pleomorphic carcinoma highly positive for PD-L1 Invited Reviewed International journal

Ikematsu Y., Yoneshima Y., Ijichi K., Tanaka K., Harada T., Oda Y, Nakanishi Y. & Okamoto I.*

Lung Cancer   2017.7

Most T790M mutations are present on the same EGFR allele as activating mutations in patients with non-small cell lung cancer Invited Reviewed International journal

Hidaka N., Iwama E*., Kubo N., Harada T., Miyawaki K., Tanaka K., Okamoto I., Baba E., Akashi K., Sasaki H. & Nakanishi Y.

Lung Cancer   75 - 82   2017.6

Treatment rationale and design for J-SONIC: a randomized study of carboplatin plus nab-paclitaxel with or without nintedanib for advanced non–small cell lung cancer with idiopathic pulmonary fibrosis Invited Reviewed International journal

2017.6

A Randomized Phase II Study Comparing Nivolumab With Carboplatin-Pemetrexed for Patients With EGFR Mutation-Positive Nonsquamous Non-Small-Cell Lung Cancer Who Acquire Resistance to Tyrosine Kinase Inhibitors Not Due to a Secondary T790M Mutation: Rationale and Protocol Design for the WJOG8515L Study Reviewed International journal

Hayashi H.*, Chiba Y., Sakai K., Fujita T., Yoshioka H., Sakai D., Kitagawa C., Naito T., Takeda K., Okamoto I., Mitsudomi T., Kawakami Y., Nishio K., Nakamura S., Yamamoto N. & Nakagawa K.

Clinical Lung Cancer   2017.5

Meta-analysis of pemetrexed plus carboplatin doublet safety profile in first-line non-squamous non-small cell lung cancer studies Reviewed International journal

Okamoto I., Schuette H., Stinchcombe T., Rodorigues-Pereira J., Antonio B., Chen J., Liu J., John W.* & Zinner R.

Current Medical Research and Opinion   937 - 941   2017.5

Chronic myelomonocytic leukemia blast crisis in a patient with advanced non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors Invited Reviewed International journal

Ogata H., Okamoto I., Yoshimoto G., Obara T., Ijichi K., Iwama E., Harada T., Akashi K. & Nakanishi Y.

Respiratory Investigation   181 - 183   2017.3

Treatment Rationale and Design for J-AXEL: A Randomized Phase 3 Study Comparing Nab-Paclitaxel With Docetaxel in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer Reviewed International journal

18 ( 1 )   100 - 103   2017.1

Monitoring of somatic mutations in circulating cell-free DNA by digital PCR and next-generation sequencing during afatinib treatment in patients with lung adenocarcinoma positive for EGFR activating mutations Invited Reviewed International journal

Iwama E., Sakai K., Azuma K., Harada T., Harada D., Nosaki K., Hotta K., Ohyanagi F., Kurata T., Fukuhara T., Akamatsu H., Goto K., Shimose T., Kishimoto J., Nakanishi Y., Nishio K. & Okamoto I.*

Annals of Oncology   136 - 141   2017.1

A phase I study of irinotecan for previously treated lung cancer patients with the 　 UGT1A1*28 or *6 polymorphism: Results of the Lung Oncology Group in Kyushu Invited Reviewed International journal

40 - 45   2017.1

Multicenter cooperative observation study of idiopathic pulmonary fibrosis with non-small cell lung cancer Invited Reviewed International journal

Ebi N, Tokunaga S, Itoh K, Okamoto I, Edakuni N, Fujii S, Watanabe K, Hayashi S, Maeyama T, Nakanishi Y.

World Journal of Respirology 2016; 6(1)   42 - 48   2016.12

Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation- positive lung adenocarcinoma: post-hoc analyses of the randomized LUX-Lung 3 and 6 trials Invited Reviewed International journal

Annals of Oncology 2016; 27(11)   2103 - 2110   2016.11

FGFR gene alterations in lung squamous cell carcinoma are potential targets for the multikinase inhibitor nintedanib Invited Reviewed International journal

Hibi M, Kaneda H, Tanizaki J, Sakai K, Togashi Y, Terashima M, De Velasco MA, Fujita Y, Banno E, Nakamura Y, Takeda M, Ito A, Mitsudomi T, Nakagawa K, Okamoto I, Nishio K.

Cancer Science   1667 - 1676   2016.11

Phase II study of erlotinib plus tivantinib (ARQ 197) in patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer just after progression on EGFR-TKI, gefitinib or erlotinib Invited Reviewed International journal

Azuma K, Hirashima T, Yamamoto N, Okamoto I, Takahashi T, Nishio M, Hirata T, Kubota K, Kasahara K, Hida T, Yoshioka H, Nakanishi K, Akinaga S, Nishio K, Mitsudomi T, Nakagawa K.

ESMO open 2016; 1(4): e000063   2016.11

Re-biopsy status among non-small cell lung cancer patients in Japan: a retrospective study Invited Reviewed International journal

Nosaki K, Satouchi M, Kurata T, Yoshida T , Okamoto I, Katakami N, Imamura F, Tanaka K, Yamane Y, Yamamoto N, Kato T, Kiura K, Saka H, Yoshioka H, Watanabe K, Mizuno K, Seto T

Lung Cancer 2016; Nov;101   1 - 8   2016.11

Phase II trial of weekly nab-paclitaxel for previously treated advanced non-small cell lung cancer: Kumamoto thoracic oncology study group (KTOSG) trial 1301 Invited Reviewed International journal

Sakata S, Saeki S, Okamoto I (Correspondence author), Otsubo K, Komiya K, Morinaga R, Yoneshima Y, Koga Y, Enokizu A, Kishi H, Hirosako S, Yamaguchi E, Aragane N, Fujii S, Harada T, Iwama E, Semba H, Nakanishi Y, Kohrogi H

Lung Cancer 2016   41 - 45   2016.9

Characteristics of Smoking Patients with Lung Cancer with Emphysematous Bullae Invited Reviewed International journal

Iwama E, Okamoto I, Yabuuchi H, Takayama K, Harada T, Matsuo Y, Tokunaga S, Baba E, Nakanishi Y

Journal of Thoracic Oncology 2016   1586 - 1590   2016.9

Anti-HER3 monoclonal antibody patritumab sensitizes refractory non-small cell lung cancer to the epidermal growth factor receptor inhibitor erlotinib Invited Reviewed International journal

Oncogene 2016; 35(7):   878 - 886   2016.7

Bevacizumab beyond disease progression after first-line treatment with bevacizumab plus chemotherapy in advanced nonsquamous non–small cell lung cancer (WJOG 5910L): an open-label, randomized, phase II trial Invited Reviewed International journal

1050 - 1059   2016.7

Characteristics and overall survival of EGFR mutation-positive non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors: A Retrospective Analysis for 1,660 Japanese patients Invited Reviewed International journal

Inoue A, Yoshida K, Morita S, Imamura F, Seto T, Okamoto I, Nakagawa K, Yamamoto N, Muto S, Fukuoka M

Japanese Journal of Clinical Oncology 2016   462 - 467   2016.5

HER2 genomic amplification in circulating tumor DNA from patients with cetuximab-resistant colorectal cancer. Invited Reviewed International journal

Takegawa N, Yonesaka K, Sakai K, Ueda H, Watanabe S, Nonagase Y, Okuno T, Takeda M, Maenishi O, Tsurutani J, Satoh T, Okamoto I, Nishio K, Tamura T, Nakagawa K.

Oncotarget 2016; 7(3)   3453 - 3460   2016.3

MET-targeted therapy for gastric cancer: the importance of a biomarker-based strategy. Invited Reviewed International journal

Kawakami H, Okamoto I

Gastric Cancer 2016   687 - 695   2016.3

Survival, quality-adjusted survival, and other clinical end points in older advanced non-small-cell lung cancer patients treated with albumin-bound paclitaxel. Reviewed International journal

Langer CJ., Hirsh V., Okamoto I., Lin FJ., Wan Y., Whiting S., Ong TJ., Renschler MF., Botteman MF.

British Journal of Cancer 2015; 113(1): 20-29   113 ( 1 )   20 - 29   2015.6

Hypermethylation of the CpG dinucleotide in epidermal growth factor receptor codon 790: implications for a mutational hotspot leading to the T790M mutation in non-small-cell lung cancer. Reviewed International journal

Fijii A., Harada T., Iwama E., Ota K., Furuyama K., Ijichi K., Okamoto T., Okamoto I., Takayama K., Nakanishi Y.

Cancer Genetics   208 ( 5 )   271 - 278   2015.5

Heterogeneity of anaplastic lymphoma kinase gene rearrangement in non-small-cell lung carcinoma: A comparative study between small biopsy and excision samples Reviewed International journal

Abe H., Kawahara A., Azuma K., Taira T., Takase Y., Fukumitsu T., Murata K., Yamaguchi T., Akiba J., Ishii H., Okamoto I., Hoshino T., Takamori S., Kage M.

Journal of Thoracic Oncology   10 ( 5 )   800 - 805   2015.5

Anti-HER3 monoclonal antibody patritumab sensitizes refractory non-small cell lung cancer to the epidermal growth factor receptor inhibitor erlotinib Reviewed International journal

Oncogene   11   2015.5

Infected complex renal cysts during crizotinib therapy in a patient with non–small cell lung cancer positive for ALK rearrangement Reviewed International journal

33 ( 2 )   510 - 512   2015.4

Phase I study of amatuximab, a novel monoclonal antibody to mesothelin, in Japanese patients with advanced solid tumors. Reviewed International journal

Fujisaka Y., Kurata T., Tanaka K., Kudo T., Okamoto K., Tsurutani J., Kaneda H., Okamoto I., Namiki M., Kitamura C., Nakagawa K.

Investigational New Drugs   33 ( 2 )   380 - 388   2015.4

Nicotine induces resistance to erlotinib via cross-talk between α 1 nAChR and EGFR in the non-small cell lung cancer xenograft model. Lung Cance Reviewed International journal

88 ( 1 )   1 - 8   2015.4

Pooled safety analysis of EGFR-TKI treatment for EGFR mutation-positive non-small cell lung cancer. Reviewed International journal

Takeda M., Okamoto I., Nakagawa K.

Lung Cancer   88 ( 1 )   74 - 79   2015.4

Circulating hepatocyte growth factor is correlated with resistance to cetuximab in metastatic colorectal cancer Reviewed International journal

Yonesaka K., Satoh T., Ueda S., Yoshida T., Takeda M., Shimizu T., Okamoto I., Nishio K., Tamura T., Nakagawa K.

ANTICANCER RESEARCH   35 ( 3 )   1683 - 1689   2015.3

The tolerability of nintedanib (BIBF 1120) in combination with docetaxel: a Phase 1 study in Japanese patients with previously treated non-small-cell lung cancer. Reviewed International journal

Okamoto I., Miyazaki M., Takeda M., Terashima M., Azuma K., Hayashi H., Kaneda H., Kurata T., Tsurutani J., Seto T., Hirai F., Konishi K., Sarashina A., Yagi N., Kaiser R., Nakagawa K.

Journal of Thoracic Oncology   10 ( 2 )   346 - 352   2015.2

The OCT4 pseudogene POU5F1B is amplified and promotes an aggressive phenotype in gastric cancer Reviewed International journal

Hayashi H., Arao T., Togashi Y., Kato H., Fujita Y., De Velasco MA., Kimura H., Matsumoto K., Tanaka K., Okamoto I., Ito A., Yamada Y., Nakagawa K., Nishio K.

Oncogene   34 ( 2 )   199 - 208   2015.1

Multiple regulatory mechanism of hepatocyte growth factor expression in malignant cells with a short poly(dA) sequence in the HGF promoter. Reviewed International journal

Sakai K., Takeda M., Okamoto I., Nakagawa K., Nishio K.

Oncology Letters   9 ( 1 )   405 - 410   2015.1

Phase II clinical trial of S-1 plus oral leucovorin in previously treated patients with non–small-cell lung cancer. Reviewed International journal

86 ( 3 )   339 - 343   2014.12

Addition of bevacizumab enhances antitumor activity of erlotinib against non-small cell lung cancer xenografts depending on VEGF expression. Reviewed International journal

Li H, Takayama K, Wang S., Shiraishi Y., Gotanda K., Harada T., Furuyama K., Iwama E., Okamoto I, Nakanishi Y

Cancer Chemother Pharmacol.   74 ( 6 )   1297 - 1305   2014.12

The anti-HER3 antibody patritumab abrogates cetuximab resistance mediated by heregulin in colorectal cancer cells Reviewed International journal

Kawakami H., Okamoto I., Yonesaka K., Okamoto K., Shibata K., Shinkai Y., Sakamoto H., Kitano M., Tamura T., Nishio K., Nakagawa K.

Oncotarget   5 ( 23 )   11847 - 11856   2014.12

Erlotinib alone or with bevacizumab as a first-line therapy in patients with advanced non-squamous non–small-cell lung cancer harbouring epidermal growth factor receptor mutations (JO25567): a randomised phase II study Reviewed International journal

15 ( 11 )   1236 - 1244   2014.10

Association of PD-L1 overexpression with activating EGFR mutations in surgically resected non-small cell lung cancer. Reviewed International journal

Azuma K., Ota K., Kawahara A., Hattori S., Iwama E., Harada T., Matsumoto K., Takayama K., Takamori S., Kage M., Hoshimo T., Nakanishi Y., Okamoto I.

Annal s of Oncology   25 ( 10 )   1935 - 1940   2014.10

Tyrosine Phosphoproteomics Identifies Both Codrivers and Cotargeting Strategies for T790M-Related EGFR-TKI Resistance in Non-Small Cell Lung Cancer. Reviewed International journal

Yoshida T., Zhang G., Smith MA., Lopez AS., Bai Y., Li J., Fang B., Koomen J., Rawal B., Fisher KJ., Chen AY., Kitano M., Morita Y., Yamaguchi H., Shibata K., Okabe T., Okamoto I., Nakagawa K., Haura EB.

Clin Cancer Res.   20 ( 15 )   4059 - 4074   2014.8

A Phase II Study of Zoledronic Acid Combined with Docetaxel for Non–small-cell Lung Cancer: West Japan Oncology Group Reviewed International journal

105 ( 8 )   989 - 995   2014.8

A phase I study of split-dose cisplatin and etoposide with concurrent accelerated hyperfractionated thoracic radiotherapy in elderly patients with limited-disease small cell lung cancer. Reviewed International journal

Okamoto K., Okamoto I., Takeda M., Kobayashi S., Takeda K., Nakamatsu K., Nishimura Y., Nakagawa K.

Japanese Journal of Clinical Oncology   44 ( 8 )   743 - 748   2014.8

CRIPTO1 expression in EGFR-mutant NSCLC elicits intrinsic EGFR-inhibitor resistance.. Reviewed International journal

Park KS., Raffeld M., Moon YW., Xi L, Bianco C., Pham T., Lee LC., Mitsudomi T., Yatabe Y., Okamoto I., Subramaniam D., Mok T., Rosell R., Luo J., Salomon DS., Wang Y., Giaccone G.

Journal of Clinical Investigation   124 ( 7 )   3003 - 3015   2014.7

Multiplex genomic profiling of non–small cell lung cancers from the LETS phase III trial of first-line S-1/carboplatin versus paclitaxel/carboplatin: results of a West Japan Oncology Group study Reviewed International journal

5 ( 8 )   2293 - 2230   2014.4

Survival outcome assessed according to tumor response and shrinkage pattern in patients with EGFR mutation-positive non-small cell lung cancer treated with gefitinib or erlotinib Reviewed International journal

Takeda K., Okamoto I., Nakagawa K.

Journal of Thoracic Oncology   9 ( 2 )   200 - 204   2014.2

Patient-Reported Neuropathy and Taxane-Associated Symptoms in a Phase 3 Trial of nab-Paclitaxel Plus Carboplatin versus Solvent-Based Paclitaxel Plus Carboplatin for Advanced Non-Small-Cell Lung Cancer. Reviewed International journal

Hirsh V., Okamoto I., Hon JK., Page RD., Orshi J., Sakai H., Zhang H., Renschler MF., Socinski MA.

Journal of Thoracic Oncology   9 ( 1 )   83 - 90   2014.1

A phase II study of cisplatin /S-1 in patients with carcinomas of unknown primary site. Reviewed International journal

Tsuya A., Kurata T., Tamiya A., Okamoto I., Ueda S., Sakai D., Sugimoto N., Matsumoto K., Goto I., Yamamoto N., Fukuoka M., Nakagawa K.

Investigational New Drugs   31 ( 6 )   1568 - 1572   2013.12

Phase I Pharmacokinetic Study of S-1 Granules and Nedaplatin for Advanced Head and Neck Cancer Reviewed International journal

Hayashi H., Okamoto I., Ueda S., Tanaka K., Okamoto K., Kawakami H., Nishina S., Takeda M., Fujisaka Y., Satoh T., Terao K., Nishimura Y., Doi K., Nakagawa K.

Anticancer Reseach   33 ( 12 )   5699 - 5705   2013.12

Human papillomavirus DNA and p16 expression in Japanese patients with oropharyngeal squamous cell carcinoma Reviewed International journal

Kawakami H., Okamoto I., Terao K., Sakai K., Suzuki M., Ueda S., Tanaka K., Kuwata K., Morita Y., Ono K., Nishio K., Nishimura Y., Doi K., Nakagawa K.

Cancer Medicine   2 ( 6 )   933 - 941   2013.12

A Randomized, Open-label, Phase III Study Comparing Irinotecan with Paclitaxel for Treatment of Advanced Gastric Cancer Refractory to Combination Chemotherapy using Fluoropyrimidine plus Platinum: WJOG4007 Trial Reviewed International journal

Hironaka S., Ueda S., Yasui H., Nishina T., Tsuda M., Tsumura T., Sugimoto N., Shimodaira H., Tokunaga S., Moriwaki T., Esaki T., Nagase M., Fujitani K., Yamaguchi K., Ura T., Hamamoto Y., Morita S., Okamoto I., Boku N., Hyodo I.

Journal of Clinical Oncology   31 ( 35 )   4438 - 4444   2013.12

A phase I, pharmacokinetic and pharmacodynamic study of nimotuzumab in Japanese patients with advanced solid tumors Reviewed International journal

Okamoto W., Yoshino T., Takahashi T., Okamoto I., Ueda S., Tsuya A., Boku N., Nishio K., Fukuoka M., Yamamoto N., Nakagawa K.

Cancer Chemotherapy and Pharmacology   72 ( 5 )   1063 - 1071   2013.11

Perturbation of the mutated EGFR interactome identifies vulnerabilities and resistance mechanisms. Reviewed International journal

Li J., Bennett K., Stukaloy A., Fang B., Zhang G., Yoshida T., Okamoto I., Kim JY., Song L., Bai Y., Qian X., Rawal B., Schell M., Grebien F., Winter G., Rix U., Eschrich S., Koomen J., Superti-Furga G., Haura EB.

5 ( 9 )   2013.11

Pemetrexed and carboplatin followed by pemetrexed maintenance therapy in chemo-naïve patients with advanced nonsquamous non-small cell lung cancer. Reviewed International journal

31 ( 5 )   1275 - 1282   2013.10

Safety and efficacy analysis by histology of weekly nab-paclitaxel in combination with carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer. Reviewed International journal

Socinski MA., Okamoto I., Hon JK., Hirsh V., Dakhil SR., Page RD., Orsini J, Yamamoto N., Zhang H., Renschler MF.

Annals of Oncology   24 ( 9 )   2390 - 2396   2013.9

Postprogression survival for first-line chemotherapy in patients with advanced gastric cancer Reviewed International journal

Kawakami H., Okamoto I., Hayashi H., Taguri M., Morita S., Nakagawa K.

European Journal of Cancer   49 ( 14 )   3003 - 3009   2013.9

Practical use of gemcitabine and cisplatin combination therapy as first-line treatment for Japanese patients with advanced biliary tract cancer Reviewed International journal

Kawakami H., Okamoto I., Okamoto W., Takeda M., Ueda S., Kudo T., Nishina S., Fujisaka Y., Miyazaki M., Tsurutani J., Kurata T., Nakagawa K.

Journal of Cancer Therapy   4 ( 6 )   1068 - 1073   2013.8

Efficacy and safety of weekly nab-paclitaxel plus carboplatin in patients with advanced non-small cell lung cancer. Reviewed International journal

Satouchi M., Okamoto I., Sakai H., Yamamoto N., Ichinose Y., Ohmatsu H., Nogami N., Takeda K., Mitsudomi T., Kasahara K., Negoro S.

Lung Cancer   81 ( 1 )   97 - 101   2013.7

A phase I study of S-1with concurrent radiotherapy in elderly patients with locally advanced non-small cell lung cancer. Reviewed International journal

Hasegawa Y., Okamoto I., Takezawa K., Miyazaki M., Tsurutani J., Yonesaka K., Morinaga R., Tsuya A., Terashima M., Kudoh T., Azuma K., Kurata T., Nishikawa T., Fukuoka M., Nishimura T., Nakagawa K.

Investigational New Drugs.   31 ( 3 )   599 - 604   2013.6

Phase II study of S-1 and carboplatin plus bevacizumab followed by maintenance S-1 and bevacizumab for chemotherapy-naïve patients with advanced nonsquamous non–small cell lung cancer. Reviewed International journal

119 ( 12 )   2275 - 2281   2013.6

Histology and smoking status predict survival of patients with advanced non-small-cell lung cancer: Results of West Japan Oncology Group (WJOG) Study 3906L. Reviewed International journal

Kogure Y., Ando M., Saka H., Chiba Y., Yamamoto N., Asami K., Hirashima T., Seto T., Nagase S., Otsuka K., Yanagihara K., Takeda K., Okamoto I., Aoki T., Takayama K., Yamasaki M., Kudoh S., Katakami N., Miyazaki M., Nakagawa K.

Journal of Thoracic Oncology   8 ( 6 )   753 - 758   2013.6

Postprogression survival in patients with advanced non-small cell lung cancer who receive second- or third-line chemotherapy Reviewed International journal

Hayashi H., Okamoto I., Taguri M., Morita S., Nakagawa K.

Clinical Lung Cancer   2013.5

Clinical impact of continued crizotinib administration after isolated central nervous system progression in patients with lung cancer positive for ALK rearrangement. Reviewed International journal

Takeda K., Okamoto I., Nakagawa K.

Journal of Thoracic Oncology   8 ( 5 )   654 - 657   2013.5

Sorting nexin2-mediated membarne trafficking of c-Met contributes to sensitivity of molecular-targeted drugs. Reviewed International journal

Ogi S., Fujita H., Kashihara M., Yamamoto C., Sonoda K., Okamoto I., Nakagawa K., Ohdo S., Tanaka Y., Kuwano M., Ono M.

Cancer Science   104 ( 5 )   573 - 583   2013.5

Efficacy and safety analysis according to histology for S-1 in combination with carboplatin as first-line chemotherapy in patients with advanced non-small cell lung cancer: updated results of the West Japan Oncology Group LETS study Reviewed International journal

Yoshioka H., Okamoto I., Morita S., Ando M, Takeda K., Seto T., Yamamoto N., Saka H., Atagi S., Hirashima T., Kudoh S., Satouchi M., Ikeda N., Iwamoto Y., Sawa T., Nakanishi Y., Nakagawa K.

Annals of Oncology   24 ( 5 )   1326 - 1331   2013.5

Phase II study of bi-weekly irinotecan for patients with previously treated HER2-negative metastatic breast cancer: KMBOG0610B. Reviewed International journal

Hayashi H., Tsurutani J., Satoh T., Masuda N., Okamoto W., Morinaga R., Terashima M., Miyazaki M., Okamoto I., Nishida Y., Tominaga S., Tokunaga Y., Yamaguchi M., Sakamoto J., Nakayama T., Nakagawa K.

Breast Cancer   20 ( 2 )   131 - 136   2013.4

Phase I and pharmacokinetic study of gefitinib and S-1 combination therapy for advanced adenocarcinoma of the lung . Reviewed International journal

Kiyota H., Okamoto I., Takeda M., Daga H., Naito T., Miyazaki M., Okada H., Hayashi H., Tanaka K., Terashima M., Azuma K., Murakami H., Takeda K., Yamamoto N., Nakagawa K.

Cancer Chemotherapy and Pharmacology   71 ( 4 )   859 - 865   2013.4

Safety and Efficacy of Weekly nab®-Paclitaxel in Combination with Carboplatin as First-line Therapy in Elderly Patients with Advanced Non-small Cell Lung Cancer. Reviewed International journal

24 ( 2 )   314 - 321   2013.2

MET amplification as a potential therapeutic target in gastric cancer. Reviewed International journal

Kawakami H., Okamoto I., Arao T., Okamoto W., Matsumoto K., Taniguchi H., Kuwata K., Yamaguchi H., Nishio K., Nakagawa K., Yamada Y.

Oncotarget   4 ( 1 )   9 - 17   2013.1

Clinical Phase I Study of Elpamotide, a Peptide Vaccine for VEGFR 2, in Patients with Advanced Solid Tumors. Reviewed International journal

Okamoto I., Arao T., Miyazaki M., Satoh T., Okamoto K., Tsunoda T., Nishio K., Nakagawa K.

103 ( 12 )   2135 - 2138   2012.12

Clinical outcome for EML4-ALK–positive patients with advanced non–small cell lung cancer treated with first-line platinum-based chemotherapy Reviewed International journal

23 ( 11 )   2931 - 2936   2012.11

Activation of HER family signaling as a mechanism of acquired resistance to ALK inhibitors in EML4-ALK-positive non-small cell lung cancer. Reviewed International journal

Tanizaki J., Okamoto I., Okabe T., Sakai K., Tanaka K., Hayashi H., Kaneda H., Takezawa K., Kuwata K., Yamaguchi H., Hatashita E., Nishio K., Nakagawa K.

18 ( 22 )   6219 - 6226   2012.11

Clinical outcome for EML4-ALK–positive patients with advanced non–small cell lung cancer treated with first-line platinum-based chemotherapy Reviewed International journal

23 ( 11 )   2931 - 2936   2012.11

Clinical Outcome of Thoracic Radiotherapy for Locally Advanced NSCLC with EGFR Mutations or EML4-ALK Reviewed International journal

Hayashi H., Okamoto I., Kimura H., Sakai K., Nishimura Y., Nishio K., Nakagawa K.

32 ( 10 )   4533 - 4537   2012.10

Impact of treatment with bevacizumab beyond disease progression: a randomized phase II study of docetaxel with or without bevacizumab after platinum-based chemotherapy plus bevacizumab in patients with advanced nonsquamous non-small cell lung cancer (WJOG 5910L) Reviewed International journal

Takeda M., Okamoto I., Yamanaka T., Nakagawa K., Nakanishi Y.

BMC cancer   12 ( 1 )   327   2012.8

Antitumor Action of the MET Tyrosine Kinase Inhibitor Crizotinib (PF-02341066) in Gastric Cancer Positive for MET Amplification. Reviewed International journal

Okamoto W., Okamoto I., Arao T., Kuwata K., Hatashita E., Yamaguchi H., Sakai K., Yanagihara K., Nishio K., Nakagawa K.

Molecular Cancer Therapeutics   11   1557 - 1564   2012.7

Safety and pharmacokinetic study of nab-paclitaxel plus carboplatin in chemotherapy-naïve patients with advanced non-small cell lung cancer. Reviewed International journal

30   1132 - 1137   2012.6

Postprogression survival for first-line chemotherapy of patients with advanced non–small cell lung cancer Reviewed International journal

23 ( 6 )   1537 - 1541   2012.6

Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC Reviewed International journal

Takeda M., Okamoto I., Tsurutani J., Oiso N., Kawada A., Nakagawa K.

Japanese Journal of Clinical Oncology   42 ( 6 )   528 - 533   2012.6

Weekly nab-Paclitaxel in Combination with Carboplatin vs Solvent-based Paclitaxel Plus Carboplatin as First-line Therapy in Patients With Advanced Non-small Cell Lung Cancer: Final Results of a Phase 3 Trial Reviewed International journal

Socinski M., Bondarenko I., Karaseva N., Makhson A., Vynnychenko I., Okamoto I., Hon J., Hirsh V., Bhar P., Zhang H., Iglesias J., Renschler M.

Journal of Clinical Oncology   30 ( 17 )   2055 - 2062   2012.6

A novel mass spectrometry–based assay for diagnosis of EML4-ALK–positive non–small cell lung cancer Reviewed International journal

7   913 - 918   2012.5

Feasibility study of two schedules of sunitinib in combination with pemetrexed in patients with advanced solid tumors. Reviewed International journal

Okamoto I., Shimizu T., Miyazaki M., Tsurutani J., Ichikwa Y., Terashima M., Takeda M., Fumita S., Ohki E., Kimura N., Hashimoto J., Nakagawa K.

Investigational New Drugs   30   639 - 646   2012.4

Phase I clinical study of the angiogenesis inhibitor TSU-68 combined with carboplatin and paclitaxel in chemotherapy-naïve patients with advanced non–small cell lung cancer Reviewed International journal

7   427 - 433   2012.2

Combined effect of ALK and MEK inhibitor in EML4-ALK-positive non-small-cell lung cancer cells Reviewed International journal

Tanizaki J., Okamoto I., Takezawa K., Sakai K., Azuma K., Kuwata K., Yamaguchi H., Hatashita E., Nishio K., Janne PA., Nakagawa K.

British Journal of Cancer   106   763 - 767   2012.2

SRPX2 is Novel Chondroitin Sulfate Proteoglycan That is Overexpressed in Gastrointestinal Cancer Reviewed International journal

Tanaka K., Arao T., Tamura D., Aomatsu K., Furuta K., Matsumoto K., Kaneda H., Kubo K., Fujita Y., KimuraH., Yanagihara K., Yamada Y., Okamoto I., Nkagawa K., Nishio K.

PLoS One   7   2012.1

Overcoming Erlotinib Resistance in EGFR Mutation-Positive Non-Small Cell Lung Cancer Cells by Targeting Survivin Reviewed International journal

Okamoto K., Okamoto I., Hatashita E., Kuwata K., Yamaguchi H., Kita A., Yamanaka K., Ono M., Nakagawa K.

Molecular Cancer Therapeutics   11   204 - 213   2012.1

Association of the expression of mutant EGFR protein as determined with mutation-specific antibodies in non-small cell lung cancer with progression-free survival after gefitinib treatment. Reviewed International journal

Azuma K., Okamoto I., Kawahara A., Taira T., Nakanishima K., Hattori S., Kinoshita T., Takeda M., Nakagawa K., Takamori S., Kuwano M., Ono M., Kage M.

Journal of Thoracic Oncology   7   122 - 127   2012.1

カルボプラチン/S-1 / オンコロジークリニカルガイド 肺癌化学療法

岡本 勇

南山堂  2015.1 

ALK変異を有すIV期 NSCLCの治療戦略 / オンコロジークリニカルガイド　

古賀 祐一郎, 岡本 勇

南山堂  2015.1 

肺癌の分子生物学と発癌機序 多段階発癌機序 / 日本臨床　最新肺癌学

吉田 健史, 岡本 勇

日本臨床社  2013.11 

治療方針　非小細胞肺癌 IV期治療の近い将来想定される変化 / 肺癌診療Q&A

岡本 勇

中外医学社  2013.11 

肺癌の診断・治療の変遷と展望 分子標的治療 / 日本臨床　最新肺癌学

河野 裕子, 岡本 勇

日本臨床社  2013.11 

肺癌合併症への対策 / 呼吸器疾患最新治療

田中 薫, 岡本 勇

南江堂  2013.2 

Practice of Oncology 非小細胞肺がん / 新臨床腫瘍学改定第3版

岡本 勇

南江堂  2012.12 

Practice of Oncology 非小細胞肺がん / 新臨床腫瘍学改定第3版

岡本 勇

南江堂  2012.12 

Practice of Oncology 非小細胞肺がん / 新臨床腫瘍学改定第3版

岡本 勇

南江堂  2012.12 

CBDCA+S-1療法 / 癌化学療法ハンドブック

岡本 勇

メデイカルビュー社  2012.8 

分子標的治療薬の臨床開発-新時代への対応- / 癌化学療法ハンドブック

岡本 勇

メデイカルビュー社  2012.8 

抗腫瘍薬 / 呼吸器研修ノート

岡本 勇

診断と治療社  2011.5 

進行非小細胞肺癌治療における免疫チェックポイント阻害剤のインパクト

岡本　勇

第10回九州がん診療シンポジウム  2018.11 

Symposia on Specific Tumors 肺がん治療の進歩 ドライバー遺伝子変異陽性進行非小細胞肺癌に対する分子標的治療

岡本　勇

第77回日本癌学会学術総会  2018.9 

パネルデイスカッション7 免疫チェックポイント阻害薬の副作用対策 免疫関連有害事象対策におけるチーム医療

岡本勇

第55回日本癌治療学会学術集会  2017.10 

ASCO/JSMO Joint Symposium Combination therapy with molecularly targeted agents in lung cancer

2017.7 

教育講演 肺癌の薬物療法

岡本勇

第15回日本臨床腫瘍学会学術集会  2017.7 

シンポジウム:1 免疫チェックポイント阻害薬の副作用とその対策 チーム医療による免疫チェックポイント阻害薬の副作用マネージメント

岡本勇

第15回日本臨床腫瘍学会学術集会  2018.7 

シンポジウム:がん分子標的治療薬の新たな展開 EGFRチロシンキナーゼ阻害剤のFirst-in-classとBest-in-class

岡本勇

第21回日本がん分子標的治療学会学術集会  2017.6 

シンポジウム:免疫チェックポイント阻害剤と肺合併症 チーム医療による免疫チェックポイント阻害薬のマネージメント

岡本勇

第57回日本呼吸器学会学術講演会  2017.4 

分子生物学的特徴に基づいた進行非小細胞肺癌に対する治療開発に関する

岡本勇

第57回日本肺癌学会総会  2016.12 

シンポジウム1 コンパニオン診断とプレシクリーニングシステム 非小細胞肺癌個別化治療におけるコンパニオン診断薬開発の現状

岡本 勇

第55回日本肺癌学会総会  2014.11 

Safety Data Analyses For First-Line Pemetrexed Plus Carboplatin in Nonsquamous Non-Small Cell Lung Cancer (ns-NSCLC) International conference

Okamoto I.

Chicago Multidisciplinary Symposium in Thoracic Oncology  2014.10 

Safety Data Analyses For First-Line Pemetrexed Plus Carboplatin in Nonsquamous Non-Small Cell Lung Cancer (ns-NSCLC) International conference

Okamoto I.

European Society of Medical Oncology(ESMO)  2014.9 

ESMO/JSCO Joint Symposium A new era of genotype-based targeted therapies for advance non-small-cell lung cancer International conference

2014.8 

シンポジウム　進行期肺がんの維持療法 Continuation maintenance for elderly patients with advanced non-small cell lung cancer

岡本 勇

第12回日本臨床腫瘍学会学術集会  2014.7 

Year in Review 4 次世代チロシンキナーゼ阻害剤による耐性克服戦略

岡本 勇

第18回日本がん分子標的治療学会  2014.6 

シンポジウム9　高齢者のがん治療の進歩 高齢者進行肺癌に対する薬物療法の現状と展望

岡本 勇

第56回日本老年医学会学術集会  2014.6 

Multiplexed Genomic Profiling of Non-Small-Cell Lung Cancer(NSCLC) Invited International conference

Okamoto I.

11th International Conference of the Asian Clinical Oncology Society (ACOS)  2014.5 

シンポジウム1 非小細胞肺癌に対する分子標的治療の役割 EGFRチロシンキナーゼ阻害剤治療の最前線

岡本 勇

第54回日本肺癌学会総会  2013.11 

ワークショップ12　75歳以上高齢者肺癌に対する治療戦略 高齢者進行非扁平上皮癌に対する薬物療法の現状と取り組み

岡本 勇

第54回日本肺癌学会総会  2013.11 

Year in Review 4 次世代チロシンキナーゼ阻害剤による耐性克服戦略

岡本 勇

第18回日本がん分子標的治療学会  2013.11 

JCA-JSMO Joint Symposium Clinical challenge for therapy based on the cancer specific genomic alterations in advanced NSCLC International conference

Okamoto I.

2013.10 

化学療法総論II　分子標的薬剤の種類

岡本 勇

日本臨床腫瘍学会第22回教育セミナー  2013.9 

ASCO/JSMO joint symposium Biomarker analyses in clinical trials for NSCLC ~ West Japan Oncology Group (WJOG) perspective ~ International conference

Okamoto I.

2013.8 

Non-Small-Cell-Lung Cancer: Molecular target International conference

Okamoto I.

Best of ASCO2013 in Japan  2013.7 

シンポジウム「新規分子標的薬と創薬基盤」 サバイビンを標的としたEGFRチロシンキナーゼ阻害剤に対する耐性克服

岡本 勇

第17回日本がん分子標的治療学会学術集会  2013.6 

Potential combination of EGFR-TKIs and survivin suppressor For EGFR-mutant advanced non-small-cell lung cancer International conference

Okamoto I.

2nd Japan Taiwan Oncology Phase I Trial Conference (JTOPIC)  2013.3 

ALK肺がんの治療戦略～個別化医療の実践～

岡本 勇

日本がん分子標的治療学会　第8回トランスレーショナルリサーチワークショップ  2013.1 

シンポジウム「個別化医療のための最新技術と臨床応用」 進行非小細胞肺癌におけるDriver oncogeneを標的とした個別化治療開発における課題と新たな試み

岡本 勇

第33回日本臨床薬理学会学術総会シンポジウム  2012.11 

シンポジウム5 –Bio-Radiation (BRT):新たな治療選択肢の確立を目指して 局所進行非扁平上皮癌におけるEGFR阻害と放射線併用療法の基礎と臨床

岡本 勇

第25回日本放射線腫瘍学術大会シンポジウム  2012.11 

シンポジウム5 –Bio-Radiation (BRT):新たな治療選択肢の確立を目指して 局所進行非扁平上皮癌におけるEGFR阻害と放射線併用療法の基礎と臨床

岡本 勇

第25回日本放射線腫瘍学術大会シンポジウム  2012.11 

ワークショップ;　分子標的治療薬の開発の現状 分子標的薬の個別化治療開発へのstrategy

岡本 勇

第53回日本肺癌学会総会  2012.11 

シンポジウム;　肺癌の克服にむけて-将来への提言- 非小細胞肺がん克服にむけた分子標的治療戦略

岡本 勇

第53回日本肺癌学会総会  2012.11 

シンポジウム;　分子標的治療薬の最前線 クリゾチニブの実地臨床における使用のポイントを問題点

岡本 勇

第53回日本肺癌学会総会  2012.11 

Challenging topics in the development of driver oncogene targeted therapies International conference

Okamoto I.

IASLC Local Symposium  2012.10 

化学療法総論II 分子標的薬剤の種類

岡本 勇

日本臨床腫瘍学会第20回教育セミナー  2012.7 

教育講演Driver Oncogene and Molecular-targeted therapies

岡本 勇

第10回日本臨床腫瘍学会学術集会  2012.7 

Symposium Biomarker-driven treatment strategies for NSCLC

2012.7 

Best of Molecular-Targeted Therapy –ASCO2012- International conference

2012.7 

非細胞肺癌における分子異常と個別化医療の実際

岡本 勇

第52回日本癌治療学会学術講演会　教育講演  2012.4 

肺癌治療のコントラバーシー-EGFR-TKIs-

岡本 勇

第52回日本呼吸器学会学術講演会シンポジウム  2012.4 

Great clinical impact of molecular-targeted therapy against driver gene alterations in advanced non-small-cell lung cancer (NSCLC)

Okamoto I.

2012.4 

Beyond EGFR-TKI based combination therapy for overcoming acquired resistance

Okamoto I.

4th West Japan Oncology Group International Symposium  2012.4 

Phase II study of oral S-1 and carboplatin plus bevacizumab with maintenance S-1 and bevacizuab as first-line therapy for advanced non-squamous non-small-cell lung cancer International conference

Okamoto I.

5th Asian Pacific Lung Cancer Congress(APLCC)  2012.2 

新規サバイビン抑制剤YM155における米国との同時開発と前臨床データ創出の経験

岡本 勇

第12回抗悪性腫瘍開発フォーラム  2012.2 

Recent advances in the treatment of metastatic NSCLC -Ready for molecular-based treatment- Invited International conference

4th Singapore Society of Oncology and Chapter of Medical Oncologist Review  2012.2 

Summary of the Japanese Respiratory Society statement for the treatment of lung cancer with comorbid interstitial pneumonia. Reviewed

Ogura T., Takigawa N., Tomii K., Kishi K., Inoue Y., Ichihara E., Homma S., Takahashi K., Akamatsu H., Ikeda S., Inase N., Iwasawa T., Ohe Y., Ohta H., Onishi H., Okamoto I., Ogawa K., Kasahara K., Karata H., Kishimoto T., Kitamura Y., Gemma A., Kenmotsu H., Sakashita H., Sakamoto S., Sekine K., Takiguchi Y., Tada Y., Toyooka S., Nakayama Y., Nishioka Y., Hagiwara K., Hanibuchi M., Fukuoka J., Minegishi Y., Yanagihara T., Yamamoto N., Yamamoto H., Gaga M., Fong KM., Powell CA., Kiura K; DLD/TO Assemblies of JRS.

Respiratory Investigation   2019.11

Localized maliignant pleural mesothelioma mimicking an anterior mediastinal tumor Reviewed

Hino T., Kamitani T., Sagiyama K., Yamasaki Y., Okamoto I., Tagawa T., Ijichi K., Yamamoto H., Yabuuchi H. & Honda H.

European Journal of Radiology Open   2019.4

First-line afatinib for the treatment of EGFR mutationpositive non-small cell lung cancer in the ‘real-world’ clinical setting

2019.1

Durable response to nivolumab in a lung adenocarcinoma patient with idiopathic pulmonary fibrosis. Reviewed

Ide M., Tanaka K., Sunami S., Asoh T., Maeyama T., Tsuruta N., Nakanishi Y. & Okamoto I (Corresponding author).

Thoracic Cancer   2018.11

Development of leptomeningeal carcinomatosis during a marked response of brain metastases to pembrolizumab in a patient with non–small cell lung cancer.

2018.10

Anticancer drug treatment for advanced lung cancer with interstitial lung disease.

Otsubo K., Okamoto I , Hamada N.& Nakanishi Y.

Respiratory Investigation. 56(4), 307-311   2018.7

がん免疫療法のバイオマーカー

井上博之, 岡本勇

日本医師会雑誌 vol.147(11)   2018.5

Metastatic Lung Adenocarcinoma Mimicking Meningioma. Reviewed

Yanagihara T., Seki N., Hiwatashi A., Arimura K., O Suzuki S. & Okamoto I.

Internal Medicine   2018.4

ターゲット次世代シークエンシング法による非小細胞肺がん患者における抗PD-1/PD-L1抗体の治療効果予測因子の同定

井上博之, 岡本勇

腫瘍内科 vol.22(4)   2018.4

分子標的薬耐性研究における次世代シーケンス解析

大坪孝平, 岩間映二, 岡本勇

がん分子標的治療 vol.16(2)   2018.4

Combined therapy with epidermal growth factor receptor tyrosine kinase inhibitors for non-small cell lung cancer.

Iwama E., Nakanishi Y. & Okamoto I.

Expert Review of Anticancer Therapy 18(3), 267-276   2018.4

非小細胞肺がんにおける免疫チェックポイント阻害剤

米嶋康臣, 岡本勇

2017.10

進行期非小細胞肺癌における免疫チェックポイント阻害薬の可能性と課題

田中謙太郎, 岡本勇

日本内科学会雑誌 106(6)   2017.10

Two cases of late-onset secondary adrenal insufficiency after discontinuation of nivolumab

Otsubo K., Nakatomi K., Furukawa R., Ashida K., Yoneshima Y., Nakanishi Y. & Okamoto I.*

Annals of Oncology   2017.8

Tumor-infiltrating lymphocyte-mediated pleuritis followed by marked shrinkage of metastatic kidney cancer of the chest wall during nivolumab treatment

Yanagihara T., Tanaka K., Ota K., Kashiwagi E., Takeuchi A., Tatsugami K, Eto M, Nakanishi Y. & Okamoto I.*

Annals of Oncology 28(8)   2017.8

Marked response to pembrolizumab in a patient with pulmonary pleomorphic carcinoma highly positive for PD-L1

Ikematsu Y., Yoneshima Y., Ijichi K., Tanaka K., Harada T., Oda Y, Nakanishi Y. & Okamoto I.*

Lung Cancer   2017.7

Severe aplastic anemia during osimertinib therapy in a patient with EGFR tyrosine kinase inhibitor-resistant non-small cell lung cancer

Ogata H., Iwama E., Yamamoto Y., Kato K., Harada T., Oda Y, Nakanishi Y. & Okamoto I.*

Journal of Thoracic Oncology 12(5)   2017.5

免疫関連有害事象と他科・他職種連携

大田恵一, 岡本勇, 中西洋一

呼吸器内科 vol.31(4),   2017.4

Chronic myelomonocytic leukemia blast crisis in a patient with advanced non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors

Ogata H., Okamoto I.,* Yoshimoto G., Obara T., Ijichi K., Iwama E., Harada T., Akashi K. & Nakanishi Y.

Respiratory Investigation 55(2),   2017.3

腫瘍微小環境に適応させた免疫学に基づくがんの併用療法

田中謙太郎, 岡本勇

腫瘍内科 vol.19(1)   2017.1

Successful Treatment with Alectinib after Crizotinib-Induced Esophageal Ulceration

Yoneshima Y., Okamoto I., Enokizu A., Iwama E., Harada T., Takayama K., Nakanishi Y.

Lung Cancer   2015.6

Infected complex renal cysts during crizotinib therapy in a patient with non–small cell lung cancer positive for ALK rearrangement

2015.4

進行非小細胞肺がん治療における血管新生阻害剤の新展開

岡本 勇

遥か EPS Magagine vol.10   2015.3

Cystic brain metastasis in non–small cell lung cancer with ALK rearrangement.

2014.12

非小細胞肺癌における血管新生阻害剤の役割

木村 信一, 岡本 勇

2014.11

Current status and future perspectives of cooperative study groups for lung cancer in Japan.

Kawano Y., Okamoto I., Fukuda H., Ohe Y., Nakamura S., Nakagawa K., Hotta K., Kiura K., Takiguchi Y., Saka H., Okamoto H., Takayama K., Semba H., Kobayashi K., Kenmotsu H., Tsuboi M., Yamamoto N., Nukiwa T., Nakanishi Y.

Respiratory Investigation   2014.11

Targeting MET amplification as a new oncogenic driver

Kawakami H., Okamoto I., Okamoto W., Tanizaki J., Nakagawa K., Nishio K.

Cancers   2014.7

内科疾患最新の治療-明日への指針-非小細胞肺がん

河野 裕子, 岡本 勇

内科 vol.113, No.6   2014.6

扁平上皮癌完全切除を対象としたウベニメクス術後補助療法の第Ⅲ相比較試験

岡本 龍郎, 岡本 勇

がん分子標的治療 vol.12, No.2   2014.6

PD-1, PD-L1を標的としたがん治療開発の課題と展望

林 秀敏, 岡本 勇

腫瘍内科 vol.13(6)   2014.6

Ⅳ期非小細胞肺癌 EGFR遺伝子変異陽性肺癌の治療

河野 裕子, 岡本 勇

コンセンサス癌治療 第13巻第2号   2014.5

Development of ALK inhibitors and molecular diagnosis in ALK rearrangement–positive lung cancer.

2014.3

高齢者進行非小細胞肺がんに対する治療開発の経緯と現状

岡本 勇, 片山 宏

腫瘍内科 vol.13, No.2   2014.2

Bilateral ovarian metastasis of non-small cell lung cancer with ALK rearrangement

Fujiwara A., MD., Kanou T., Tokunaga T., Oami J., Kodama K., Nishino K., Tomita Y., Okamoto I.

Lung Cancer   2014.2

非小細胞肺がんにおける血管新生阻害剤の現状

岡本 勇

がん分子標的治療 vol.11, No.2   2014.1

個別化医療を目的としたバイオマーカーのコンパニオン開発 EGFRチロシンキナーゼ阻害剤使用におけるEGFR遺伝子検査

岩間 映二, 岡本 勇

腫瘍内科 vol.12(6)   2013.12

Bronchoscopic findings for bevacizumab-related pulmonary hemorrhage in advanced non-small cell lung cancer.

Okamoto K., Okamoto I., Miyazaki M., Tanaka K., Kaneda H., Nakagawa K

Investigational New Drugs   2013.10

Clinical response to crizotinib retreatment after acquisition of drug resistance.

Matsuoka H., Kurata T., Okamoto I., Kaneda H., Tanaka K., Nakagawa K.

Journal of Clinical Oncology   2013.7

Molecularly targeted approaches herald a new era of non–small cell lung cancer treatment.

2013.6

Rapid response of brain metastasis to crizotinib in a patient with ALK rearrangement-positive non-small cell lung cancer.

Kaneda H., Okamoto I., Nakagawa K.

Journal of Thoracic Oncology   2013.4

分子標的薬を併用した化学放射線治療の可能性

林 秀敏, 岡本 勇

腫瘍内科 vol.11, No.1   2013.1

Severe acute interstitial lung disease after crizotinib therapy in a patient with EML4-ALK–positive non–small cell lung cancer.

2013.1

肺癌個別化治療におけるバイオマーカー

岡本 邦男, 岡本 勇

呼吸と循環 vol.60, No.12   2012.12

腫瘍性疾患の分子標的薬 非小細胞肺がん

岡本 勇

日本臨床増刊号 分子標的薬 vol.70, Supple 8   2012.11

Oncogenic addictionと分子標的治療

光冨 徹哉, 間野 博行, 岡本 勇

がん分子標的治療 vol.10, No.3   2012.10

進行非小細胞肺癌における｢維持療法｣のエビデンス

田中 薫, 岡本 勇

日本胸部臨床 vol.71, No.10   2012.10

当科における肺門および縦隔リンパ節腫大の診断におけるEBUS-TBNAの有用性の検討

金田 裕康, 宮崎 昌樹, 清田 秀美, 田中 薫, 林 秀敏, 鶴谷 純司, 倉田 宝保, 岡本 勇, 中川 和彦

気管支学 vol.34, No.5   2012.9

Marked response to both S-1 and pemetrexed in a patient with echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase-positive lung adenocarcinoma

Kaneda H., Okamoto I., Sakai K., Tanizaki J., Takeda M., Nishio K., Nakagawa K.

Acta Oncologica   2012.9

Reversible posterior leukoencephalopathy syndrome and trastuzumab.

Kaneda H., Okamoto I., Satoh T., Nakagawa K.

Investigational New Drugs   2012.8

EML4-ALK-targeted therapy for advanced non-small cell lung cancer: molecular and clinical aspects

Okamoto I., Nakagawa K.

Cancer Science   2012.8

新たな標的となる遺伝子とその変異, 新薬 EGFR 遺伝子変異

林 秀敏, 岡本 勇

最新医学 vol.67   2012.6

新規サバイビン抑制剤YM155における米国との同時開発と前臨床データ創出の経験

岡本 勇

腫瘍内科 vol.9, No.5   2012.5

Capecitabine Plus Cisplatin Treatment for Advanced Gastric Cancer in a Patient with Hepatic Impairment Secondary to Metastases

Kawakami H., Nishina S., Ueda S., Kudo T., Okamoto W., Kurata T., Okamoto I., Nakagawa K.

Gastrointestinal Cancer Research   2012.5

肺がんでの個別化医療の試み

岡本 勇, 坂井 和子, 中川 和彦, 西尾 和人

最新医学 vol.67, No.5   2012.5

ASCOによるEGFR-TKI使用に関するprovisional opinionについて

金田 裕康, 岡本 勇

腫瘍内科 vol.9, No.5   2012.5

Perirenal hematoma associated with Bevacizumab

Hayashi H., Okamoto I., Nakagawa K.

Investigational New Drugs   2012.4

肺癌における治療標的としてのMET

谷崎 潤子, 岡本 勇

医学のあゆみ vol.240, No.13   2012.3

Pharmacokinetics of docetaxel in a patient with non–small cell lung cancer undergoing continuous ambulatory peritoneal dialysis

2012.3

Successful long-term treatment with pemetrexed of NSCLC associated with EML4-ALK and low thymidylate synthase expression.

Takeda M., Okamoto I., Sakai K., Tanaka K., Terashima M., Nishio K., Nakagawa K.

Clinical Lung Cancer   2012.3

抗体療法 3)固形がんの抗体療法

川上 尚人, 岡本 勇

腫瘍内科 vol.8, No.5   2011.11

Nimotuzumab, a novel monoclonal antibody to the epidermal growth factor receptor, in the treatment of non–small cell lung cancer.

2011.10

非小細胞肺癌とエルロチニブ

武田 真幸, 岡本 勇

癌と化学療法 vol.38,No.6   2011.6

肺癌の病態と治療 非小細胞肺癌の治療 化学療法

林 秀敏, 岡本 勇

からだの科学 vol.270   2011.6

EML4-ALK融合遺伝子とALK阻害剤

岡本 勇

2011.6

小分子化合物の臨床開発における患者選択の重要性

岡本 勇

医薬ジャーナル vol.47, No.5   2011.5

特集パラダイムシフトを迎えた肺がん治療 組織型からみた非小細胞肺癌治療選択

林 秀敏, 岡本 勇

呼吸器内科 vol.19, No.4   2011.4

特集パラダイムシフトを迎えた肺がん治療 組織型からみた非小細胞肺癌治療選択

林 秀敏, 岡本 勇

呼吸器内科 vol.19, No.4   2011.4

非小細胞肺癌の治療戦略 EGFR-TKIに関する最近の知見

林 秀敏, 岡本 勇

外来癌化学療法 vol.1, No.2   2010.10

The emerging role of epidermal growth factor receptor (EGFR) inhibitors in first-line treatment for patients with advanced non-small cell lung cancer positive for EGFR mutations

Okamoto I., Mitsudomi T., Nakagawa K., Fukuoka M.

Therapeutic Advences in Medical Oncology.   2010.9

Successful treatment with erlotinib after gefitinib-induced severe interstitial lung disease.

Takeda M., Okamoto I., Makimura C., Fukuoka M., Nakagawa K.

Journal of Thoracic Oncology   2010.7

Successful treatment with erlotinib after gefitinib-related severe hepatotoxicity

Takeda M., Okamoto I., Fukuoka M., Nakagawa K.

Journal of Clinical Oncology   2010.6

新規分子標的薬の開発と肺癌個別化治療の可能性

中川 和彦, 武田 真幸, 岡本 勇

最新医学 vol.65, No.3   2010.3

EGFR-TK阻害薬の耐性克服を目指して

林 秀敏, 岡本 勇

呼吸器内科 vol.17, No.3   2010.3

非小細胞肺癌における抗EGFR抗体治療 ―現状とバイオマーカーに基づく今後の可能性―

米阪 仁雄, 岡本 勇

最新医学 vol.65,No.3   2010.3

ゲフィチニブ, エルロチニブ 薬理作用と治療の実際

林 秀敏, 岡本 勇

薬局 vol.61, No.2   2010.2

Epidermal growth factor receptor in relation to tumor development: EGFR-targeted anticancer therapy.

Okamoto I.

FEBS Journal   2010.1

S-1: a new oral fluoropyrimidine in the treatment of patients with advanced non-small-cell lung cancer. Clinical Lung Cancer

Okamoto I., Fukuoka M.

2009.7

Zoledronic acid-induced regression of multiple metastases at nonskeletal sites.

Okamoto K., Tsurutani J., Terashima M., Okamoto I., Nakagawa K.

Annals of Oncology   2009.4

Pharmacokinetic analysis of carboplatin and etoposide in a small cell lung cancer patient undergoing hemodialysis.

Takezawa K., Okamoto I., Fukuoka M., Nakagawa K.

Journal of Thoracic Oncology   2008.9

Overview of chemoradiation clinical trials for locally advanced non-small cell lung cancer in Japan.

Okamoto I.

International Journal of Clinical Oncology   2008.4

Large cell neuroendocrine carcinoma of the mediastinum with α-fetoprotein production.

2008.2

Sequential occurrence of non-small cell and small cell lung cancer with the same EGFR mutation.

Morinaga R., Okamoto I., Furuta K., Kawano Y., Sekijima M., Dote K., Satou T., Nishio K., Fukuoka M., Nakagawa K.

Lung Cancer   2007.12

Amrubicin for non-small-cell lung cancer and small-cell lung cancer.

Kurata T., Okamoto I., Tamura K., Fukuoka M.

Investigational New Drugs   2007.10

Pemetrexed-induced edema of the eyelid.

Kurata T., Tamura K., Okamoto I., Satoh T., Nakagawa K., Fukuoka M.

Lung Cancer   2006.11

EGFR mutation in gefitinib-responsive small-cell lung cancer.

Okamoto I., Araki J., Suto R., Shimada M., Nakagawa K., Fukuoka M.

Annals of Oncology   2006.6

Efficacy of the tyrosine kinase inhibitor gefitinib in a patient with metastatic small cell lung cancer.

Araki J., Okamoto I., Suto R., Ichikawa Y., Sasaki J.

Lung Cancer   2005.4

Successful treatment of primary pulmonary angiosarcoma.

Kojima K., Okamoto I., Ushijima S., Yoshinaga T., Kitaoka M., Suga M., Sasaki Y.

Chest   2003.12

Pulmonary toxicity due to chemotherapy how is the risk and benefit from ZD1839 treatment against non-small cell lung cancer?

Okamoto I., Suga M.

Internal Medicine   2003.10

Absence of gallium uptake in unicentric and multicentric Castleman's disease

Okamoto I., Iyonaga K., Fujii K., Mori T., Yoshioka M., Kohrogi H., Matsumoto M., Suga M.

Internal Medicine   2003.8

Diffuse alveolar damage after ZD1839 therapy in a patient with non-small cell lung cancer.

Okamoto I., Fujii K., Matsumoto M., Terasaki Y., Kihara N., Kohrogi H., Suga M.

Lung Cancer   2003.6

Japan Society of Clinical Oncology

The Japanese Association for Molecular Target Therapy of Cancer

Executive   Domestic

2014.6 - Present   

Councilor   Domestic

2012.9 - 2020.10   

日本臨床腫瘍学会   学術企画委員会委員   Domestic

2011.4 - Present   

Councilor   Domestic

2009.6 - 2020.7   

日本臨床腫瘍学会   教育セミナー運営部会委員   Domestic

2009.4 - 2011.7   

Councilor   Domestic

2009.3 - 2013.7   

Councilor   Domestic

2008.11 - 2019.11   

ネクチンによる免疫チェックポイント分子リガンドの制御機構の解明

2023

腫瘍微小環境における慢性炎症の包括的理解に基づく、肺癌抗腫瘍免疫抑制機構の解明と新規治療戦略開発

2022

TP53遺伝子変異がEGFRチロシンキナーゼ阻害剤耐性に及ぼす影響とその克服を目指した研究

2022

新規の肺癌発症予防戦略に繋げる、IL-1による免疫チェックポイント発現制御機構解明

2022

免疫チェックポイント分子リガンドの制御機構の解明

2022

腫瘍微小環境における慢性炎症の包括的理解に基づく、肺癌抗腫瘍免疫抑制機構の解明と新規治療戦略開発

2022

非小細胞肺癌におけるHERファミリーの細胞内動態の解明とEGFRチロシンキナーゼ阻害剤耐性克服への応用

2022

日本医療研究開発機構革新的がん医療実用化研究事業『進行非小細胞肺癌に対する複合免疫療法の標準治療確立のためのランダム化比較第III相試験』

2021.3 - 2026.5

国立大学法人九州大学 

進行非小細胞肺癌に対する複合免疫療法の標準治療確立のためのランダム化比較第III相試験

Grant number：22ck0106669h0002  2021 - 2023

科学研究費助成事業  AMED

悪性中皮腫患者に対するコクサッキーウイルスA11を用いた腫瘍溶解性ウイルス療法の開発

Grant number：21lm0203009j0005  2021

科学研究費助成事業  AMED

高齢者切除不能局所進行非小細胞肺癌に対する化学放射線療法のランダム化比較第III相試験

Grant number：21ck0106684s0201  2021

科学研究費助成事業  AMED

腫瘍微小環境における包括的慢性炎症理解に基づく、肺癌抗腫瘍免疫抑制機構の解明

2021

特発性肺線維症合併非小細胞肺癌における線維性肺組織および腫瘍組織のTMB測定法を用いたペア解析

2021

Hippo経路分子MOB1に着目したEGFR変異陽性肺癌の新規標的治療法開発

2021

腫瘍微小環境における慢性炎症の包括的理解に基づく、肺癌抗腫瘍免疫抑制機構の解明と新規治療戦略開発

2021

成人固形がんに対する標準治療確立のための基盤研究

Grant number：2020-J-3  2020 - 2024

科学研究費助成事業  国立がん研究センター　研究開発費

呼吸器科 肺がんグループへの奨学寄附金

2020

抗PD-1抗体のバイオマーカーとしてのmiRNAの探索とその役割の解明

2020

非小細胞肺癌におけるIL-1b誘導性の免疫チェックポイント分子制御機構の解明

2020

肺腺癌におけるHippo経路分⼦MOB4の機能解析

2020

研究課題：EGFRチロシンキナーゼ阻害剤（Afatinib/Osimertinib）のヒト免疫細胞における細胞免疫学的検討 内容：種々のEGFR-TKI製剤による様々な有害事象を認め、比較的頻度の高い皮膚障害部位には種々のCD4陽性T細胞等の免疫細胞の浸潤が報告されており、ステロイド剤使用により症状の寛解を認めることからEGFR-TKIによる免疫細胞への影響が示唆される。また、近年の前臨床研究報告では、ErlotinibによるEGFR-Tgマウスにおける腫瘍浸潤マウスDCのclass II発現の増強を認める。さらに、化合物（203種類）と遺伝子（約8000種）の2つの網羅的in vitroスクリーニング系からT細胞殺細胞活性を増強する薬剤代謝経路としてEGFR-TKI（Erlotinib）及びEGFR経路が同定されており、実際にin vivo MC38担癌マウスモデルでAfatinib追加によりPD-1治療のT細胞抗腫瘍活性が増強を認めている。以上の背景から、種々のEGFR-TKI製剤の抗腫瘍免疫系を増強するメカニズムが示唆される。しかしながら、EGFR-TKI製剤のヒト免疫細胞への免疫学的影響についての報告はほとんどなされていない。 本研究では、第二世代、第三世代EGFR-TKIであるAfatinib及びOsimertinib処理による各種ヒト免疫細胞（抗原提示細胞である樹状細胞及びT細胞）への細胞免疫学的影響について検証することを目的とする。

2019.10 - 2021.9

受託研究

進行非扁平上皮非小細胞肺癌に対するカルボプラチン+ペメトレキセド+アテゾリズマブ療法とカルボプラチン+ペメトレキセド+アテゾリズマブ+ベバシズマブ療法の多施設共同オープンラベル無作為化第III相比較試験（医師主導治験WJOG11218L）

2019.1 - 2023.1

九州大学 

特発性肺線維症合併進行非小細胞肺癌に対する標準治療開発に関する研究

Grant number：21ck0106493h0003  2019 - 2021

科学研究費助成事業  AMED

呼吸器科 肺がんグループへの奨学寄附金

2019

非小細胞肺癌における薬物療法による免疫原性細胞死誘導能の探索研究

2019

非小細胞肺癌におけるProximity Ligation Assayを用いたHERヘテロダイマーの定量解析

2019

血管新生阻害剤併用プラチナ併用免疫療法における新規バイオマーカー開発

2019

Th2免疫応答を標的とした新規併用がん免疫療法の基礎研究

2019

HER2遺伝子変異陽性肺癌に対する分子標的治療薬開発に関する研究

2019

肺がんに対するPD-1阻害剤のバイオマーカーとしてのmiRNAの探索とその役割の解明

2019

呼吸器科 肺がんグループへの奨学寄附金

2019

日本医療研究開発機構革新的がん医療実用化研究事業『次世代シークエンサーによる網羅的がん関連遺伝子パネル解析を用いたHER2遺伝子変異陽性の進行非小細胞肺癌に対する治療開発を目指した研究』

2018.10 - 2022.3

九州大学 

次世代シークエンサーによる網羅的がん関連遺伝子パネル解析を用いたHER2遺伝子変異陽性の進行非小細胞肺癌に対する治療開発を目指した研究

Grant number：21ck0106449h0004  2018 - 2021

科学研究費助成事業  AMED

呼吸器科 肺がんグループへの奨学寄附金

2018

肺癌細胞における化学療法、分子標的療法による免疫原性細胞死誘導の検討

2018

小細胞肺癌の薬剤有効性・耐性に関するバイオマーカー研究

2018

特発性肺線維症（IPF）を合併する非小細胞肺癌の遺伝子プロファイルを次世代シークエンサーにて検討する観察研究

2018

小細胞肺癌におけるDLL3の発現機構解析

2018

抗PD-1/PD-L1抗体のバイオマーカーとしてのmiRNAの探索とその役割の解明

2018

小細胞肺癌の薬剤有効性・耐性にかかわるバイオマーカー解析

2018

胸部疾患研究施設への奨学寄附

2018

日本医療研究開発機構革新的がん医療実用化研究事業『特発性肺線維症合併進行非小細胞肺癌に対する標準治療開発に関する研究』

2017.5 - 2022.3

九州大学 

PD-1阻害抗体の抗腫瘍効果を増強するミトコンドリア活性化剤を用いた新規併用治療法の開発

Grant number：19lk1403006h0003  2017 - 2019

科学研究費助成事業 

成人固形がんに対する標準治療確立のための基盤研究

Grant number：29-A-3  2017 - 2019

科学研究費助成事業  国立がん研究センター　がん研究開発費

高齢者進行非扁平上皮非小細胞肺癌に対する標準的化学療法の確立に関する研究

Grant number：18ck0106344h0002  2017 - 2018

科学研究費助成事業  AMED

Notch下流分子DLL3の小細胞肺癌における発現解析

2017

ドライバー遺伝子異常をもつ非小細胞肺癌におけるPD-L1発現の検討

2017

小細胞肺癌におけるDLL3発現と患者背景因子及び予後との相関に関する後方視的研究

2017

EGFR遺伝子変異陽性進行非扁平上皮非小細胞肺癌に対する ゲフィチニブ単剤治療とゲフィチニブにシスプラチン+ペメトレキセドを途中挿入する治療との ランダム化比較試験（JCOG1404/WJOG8214L:AGAIN）

Grant number：21ck0106492h0003  2016 - 2021

科学研究費助成事業  AMED

既治療の進行・再発非小細胞肺癌に対するドセタキセルとnab-パクリタキセルのランダム化比較第III相試験

2015.4 - 2021.4

国立大学法人九州大学 

研究課題：既治療の進行・再発非小細胞肺癌に対するドセタキセルとnab-パクリタキセルのランダム化比較第III相試験（J-AXEL） 内容： 背景： 既治療進行非小細胞肺癌患者に対する新たな標準治療確立を目的とし、ドセタキセル（DTX）単剤療法に対するnab-パクリタキセル（PTX）単剤療法の有効性、安全性を検証するラムダム化比較第Ⅲ相試験を実施した。 方法： 前治療2レジメン以内の既治療進行非小細胞肺癌、20歳以上、PS0-1の患者をnab-PTXもしくはDTX治療群に1:1に無作為に割り付けた。主要評価項目は全生存期間としnab-PTXのDTXに対する非劣性を検証する。無増悪生存期間、奏効割合、有害事象発生割合およびQOLを副次評価項目とした。 結果： 2015年5月から2018年3月の間に82施設から503例が登録された。男性が348例（69.2%）、非扁平上皮癌が403例（80.1%）、EGFR遺伝子変異陽性が115例（22.9%）、ICIでの前治療歴ありが68例（13.5%）であった。2019年5月時点での有害事象は、DOCでGrade3以上の発熱性好中球減少症（18.1% vs 0.7%）が多くnab-PTXで全Gradeの末梢神経障害（47.3% vs 15.5%）が多かった。登録終了後1.5年時の観察イベント数（387）が必要イベント数を下回ったため、2020年3月まで追跡期間を延長し、2020年7月に最終解析を実施する。 結語： 本試験はnab-PTXの有用性をDTXと比較した世界初の第Ⅲ相試験であり、主要評価項目の解析結果を本学会にて初めて公表する。

2015.4 - 2021.3

受託研究

EGFR遺伝子変異陽性非小細胞肺癌における癌幹細胞マーカーCD44vの機能解析

Grant number：15K06874  2015 - 2017

日本学術振興会  科学研究費助成事業  基盤研究(C)

高齢者の小細胞肺癌に対する新たな標準治療の確立に関する研究

2015 - 2017

科学研究費助成事業  AMED

癌幹細胞を標的とした進行非扁平上皮非小細胞肺癌におけるシスプラチン+ペメトレキセド+スルファサラジン併用療法の第I相試験(医師主導治験)

2014 - 2016

科学研究費助成事業  地域連携推進研究費

ALK融合遺伝子陽性のⅢ期非小細胞肺癌に対する集学的治療法の開発に関する研究

Grant number：15Ack0106041h0002  2014 - 2016

科学研究費助成事業  日本医療研究開発機構研究費

アンメットメディカルニーズにおける抗がん薬のPK/PDに基づく最適化医療の実施

Grant number：15Ack0106112h0002  2014 - 2016

科学研究費助成事業  日本医療研究開発機構研究費

高齢者進行非扁平上皮非小細胞肺癌に対する標準的化学療法の確立に関する研究

Grant number：16ck0106072h0003  2014 - 2016

科学研究費助成事業  AMED

Liquid Biopsyによる分子標的薬の治療感受性・抵抗性の予測および新規獲得耐性機序の解明

2014 - 2016

科学研究費助成事業  日本医療研究開発機構研究費

未承認薬の早期臨床開発試験における薬物動態・薬力学解析・薬理遺伝学解析の標準化に関する研究

2014 - 2016

国立がん研究センター　がん研究開発費

成人固形がんに対する標準治療確立のための基盤研究

2014 - 2016

国立がん研究センター　がん研究開発費

抗悪性腫瘍薬の新規臨床薬理研究手法の開発に関する研究

2013

国立がん研究センター　がん研究開発費

非扁平上皮非小細胞肺癌に対するペメトレキセドを用いた術後補助化学療法

2012 - 2016

科学研究費助成事業  厚生労働科学研究費補助金 (厚生労働省)

ＭＥＴ遺伝子増幅胃癌におけるＭＥＴチロシンキナーゼ阻害剤の抗腫瘍効果の解析

2012 - 2014

日本学術振興会  科学研究費助成事業  基盤研究(C)

進行非小細胞肺癌における癌関連遺伝子の網羅的解析による治療標的分子探索研究

2012 - 2014

日本学術振興会  科学研究費助成事業  基盤研究(C)

進展型小細胞肺癌に対する予防的全脳照射の実施の有無を比較するランダム化比較第III相試験

2012 - 2014

科学研究費助成事業  厚生労働科学研究費補助金 (厚生労働省)

ＥＧＦＲチロシンキナーゼ阻害剤によるアポトーシスにおけるサバイビンの役割

2011 - 2013

日本学術振興会  科学研究費助成事業  基盤研究(C)

ＥＭＬ４−ＡＬＫ陽性肺癌におけるシグナル伝達経路の解析

2011 - 2013

日本学術振興会  科学研究費助成事業  基盤研究(C)

セツキシマブの感受性及び耐性機構の解析

2011 - 2013

日本学術振興会  科学研究費助成事業  基盤研究(C)

頭頸部腫瘍に対する強度変調放射線治療の確立と標準化のための臨床研究

2011 - 2013

科学研究費助成事業  厚生労働科学研究費補助金 (厚生労働省)

新しい薬物療法の導入とその最適化に関する研究

2010 - 2012

科学研究費助成事業  厚生労働科学研究費補助金 (厚生労働省)

ＥＧＦＲチロシンキナーゼ阻害剤獲得耐性の分子メカニズムに基づいた耐性克服研究

2009 - 2011

日本学術振興会  科学研究費助成事業  基盤研究(C)

進展型小細胞肺がんに対する予防的全脳照射のランダム化比較第３相試験

Grant number：08849893  2008 - 2010

科学研究費助成事業  厚生労働科学研究費補助金 (厚生労働省)

原発不明がんの診断・効果的治療の確立に関する研究

Grant number：07808243  2007 - 2009

科学研究費助成事業  厚生労働科学研究費補助金 (厚生労働省)

臨床医学III-②

2021.4 - 2021.9   First semester